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1. INTRODUCTION 
 For many decades treatment of acute disease or chronic illness has been mostly 
accomplished by delivery of drugs to patients using various pharmaceutical dosage forms 
including tablets, pills, suppositories, creams, ointments, liquids, aerosols, and 
injectables.  This type of drug delivery system is known to provide a prompt release of 
drug. Therefore, to achieve as well as to maintain the effective range needed for 
treatment, it is necessary to take this type of delivery system several times a day. In order 
to overcome this criteria the specialized drug delivery system, by which a 
pharmacologically active moiety may be continuously delivered or monitored either 
systematically or to target site in an effective, reliable, repeatable and safe manner has 
been introduced. These system are also capable of delivering the desired concentration of 
drug in a fixed, predetermined pattern for a definite time period. Thus necessary side 
effects are avoided and a delivery of a desired concentration of drug in a fixed, 
predetermined pattern at a precise time is made possible. 
 “The active ingredient in a medicine is only a part of the arsenal against a disease. 
The drug must somehow get to the right place at the right time. That is where the drug 
comes in” 
 Oral controlled release (CR) dosage forms have been developed over the past 
three decades due to their considerable therapeutic advantages such as ease of 
administration, patient compliance and flexibility in formulation. 
1.1. Floating drug delivery system
1
 
Floating drug Delivery System: 
 Floating drug delivery systems (FDDS) or hydro dynamically controlled systems 
are low-density systems that have sufficient buoyancy to float over the gastric contents 
and remain buoyant in the stomach without affecting the gastric emptying rate for a 
prolonged period of time. While the system is floating on the gastric contents, the drug is 
released slowly at the desired rate from the system. After release of drug, the residual 
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system is emptied from the stomach. This results in an increased Gastric retention time 
and a better control of the fluctuations in plasma drug concentration. However, besides a 
minimal gastric content needed to allow the proper achievement of the buoyancy 
retention principle, a minimal level of floating force (F) is also required to keep the 
dosage form reliably buoyant on the surface of the meal Many buoyant systems have 
been developed based on granules, powders, capsules, tablets, laminated films and 
hollow microspheres. 
Classification of Floating Drug Delivery System:  
A. Effervescent system 
 • Gas generating system 
 • Volatile liquid containing system 
B. Non-effervescent System: 
 • Colloidal gel barrier system. 
 • Alginate beds. 
 • Hollow microspheres / Microballons. 
 • Intragastric Floating Drug Delivery Device / Microporous 
   compartment system 
A. Effervescent Systems: 
 These are matrix types of systems prepared with the help of swellable polymers 
such as methylcellulose and chitosan and various effervescent compounds, eg, sodium 
bicarbonate, tartaric acid, and citric acid. They are formulated in such away that when in 
contact with the acidic gastric contents, CO2 is liberate and gas entrapped in swollen 
hydrocolloids which provides buoyancy to the dosage forms. 
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a. Volatile liquid containing systems: 
 The GRT of a drug delivery system can be sustained by incorporating an 
inflatable chamber, which contains a liquid(like ether, cyclopentane), that gasifies at body 
temperature cause the inflatation of the chamber in the stomach. The device may also 
consist of a bio-erodible plug made up of PVA, Polyethylene, etc. that gradually 
dissolves and causing the inflatable chamber to release gas and collapse after a 
predetermined time to permit the spontaneous ejection of the inflatable systems from the 
stomach. 
b. Gas-generating Systems: 
 These buoyant delivery systems utilize effervescent reactions between 
carbonate/bicarbonatesalts and citric/tartaric acid to liberate CO2, which gets entrapped in 
the gellified hydrocolloid layer of the systems thus decreasing its specific gravity and 
making it to float over chyme. How the dosage form float is shown in the figure 1. 
 
Figure 1: Gas-generating Systems 
B. Non-effervescent systems: 
 Non-effervescent floating dosage forms use a gel forming or swellable cellulose 
type hydrocolloids, polysaccharides, and matrix-forming polymers like polycarbonate, 
polyacrylate, polymethacrylate, and polystyrene. The formulation method includes a 
simple approach of thoroughly mixing the drug and the gel-forming hydrocolloid. After 
oral administration this dosage form swells in contact with gastric fluids and attains a 
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bulk density of < 1. The air entrapped within the swollen matrix imparts buoyancy to the 
dosage form. The so formed swollen gel-like structure acts as a reservoir and allow 
sustained release of drug through the gelatinous mass. 
a. Colloidal gel barrier systems: 
 Hydro dymamically balance system (HBSTM) was first design by Sheth and 
Tossounian in 1975.Such systems contains drug with gel forming hydrocolloids meant to 
remain buoyant on stomach contents. This system incorporate a high level of one or more 
gel forming highly swellable cellulose type hydrocolloids. e.g. HEC, HPMC, NaCMC, 
Polysacchacarides and matrix forming polymer such as polycarbophil, polyacrylates and 
polystyrene, incorporated either in tablets or in capsule. On coming in contact with 
gastric fluid, the hydrocolloid in the system hydrates and forms a colloidal gel barrier 
around the gel surface. The air trapped by the swollen polymer maintains a density less 
than unity and confers buoyancy to these dosage form. 
b. Alginate beads: 
 Multi-unit floating dosage forms have been developed from freeze-dried calcium 
alginate. Spherical beads of approximately 2.5 mm in diameter can be prepared by 
dropping sodium alginate solution into aqueous solution of calcium chloride, causing the 
precipitation of calcium alginate. The beads are then separated, snap-frozen in liquid 
nitrogen, and freeze-dried at -40ºC for 24 hours, leading to the formation of a porous 
system, which can maintain a floating force for over 12 hours. 
c. Hollow microspheres: 
 Hollow microspheres (microballons), loaded with ibuprofen in their outer 
polymer shells were prepared by a novel emulsion-solvent diffusion method. The ethanol: 
dichloromethane solution of the drug and an enteric acrylic polymer was poured in to an 
agitated aqueous solution of PVA that was thermally controlled at 40°C. The gas phase 
generated in dispersed polymer droplet by evaporation of dichloromethane formed in 
internal cavity in microspheres of the polymer with drug. The microballons floated 
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continuously over the surface of acidic dissolution media containing surfactant for greater 
than 12 hours in vitro. 
d. Intragastric / Microporous compartment system:  
 The system composed of a drug reservoir encapsulated in a microporous 
compartment having pores on top and bottom surfaces. The peripheral walls of the 
reservoir compartment were completely sealed to prevent any physical contact of the un 
dissolved drug with walls of the stomach. Novel levodopa gastro retentive dosage form 
based on unfolding polymeric membranes which combines extended dimensions with 
high rigidity. It was folded into a large size gelatin capsules. In vitro studies showed that 
unfolded form reached within 15 minutes after administration and it was confirmed in 
vivo in beagle dogs. The unfolded form was maintained for at least 2 hours. It was 
concluded that this dosage form could improve therapy of different narrow absorption 
window drugs. However, there are possibilities of the polymeric films to get stuck in the 
esophagus causing extreme discomfort to the patient or drug related injuries and repeated 
administration of rigid dosage form may result in gastric obstruction. 
Advantages: 
 Floating dosage systems form important technological drug delivery systems with 
gastric retentive behavior and offer several advantages in drug delivery. 
These advantages include: 
1. Floating dosage forms such as tablets or capsules will remains in the solution for 
prolonged time even at the alkaline pH of the intestine. 
 
2. FDDS dosage forms are advantageous in case of vigorous intestinal movement 
and in diarrhoea to keep the drug in floating condition in stomach to get a 
relatively better response. 
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3. Acidic substance like aspirin causes irritation on the stomach wall when come in 
contact with it hence; HBS/FDDS formulations may be useful for the 
administration of aspirin and other similar drugs. 
 
4. The FDDS are advantageous for drugs absorbed through the stomach eg: Ferrous 
salts, Antacids. Improved drug absorption, because of increased GRT and more 
time spent by the dosage form at its absorption site . 
 
5. Controlled delivery of drugs. It minimizes the mucosal irritation by releasing drug 
slowly. 
 
6. Treatment of gastrointestinal disorders such as gastro esophageal reflux. 
Disadvantages of floating drug delivery system: 
1. Floating system is not feasible for those drugs that have solubility or stability 
problem in GI tract. 
 
2. These systems require a high level of fluid in the stomach for drug delivery to 
float and work efficiently coat, water. 
 
3. The drugs that are significantly absorbed throughout gastrointestinal tract, which 
undergo significant first pass metabolism, may not be desirable candidate. E.g. 
Nifedipine. 
 
4. The ability of drug to remain in the stomach depends upon the subject being 
positioned upright. 
 
5. The residence time in the stomach depends upon the digestive state. Hence, FDDS 
should be administered after the meal. 
 
6. Not suitable for drugs that cause gastric lesions e.g. Non steroidal anti 
inflammatory drugs. Drugs that are unstable in the strong acidic environment, 
these systems do not offer significant advantages over the conventional dosage 
forms. 
Introduction 
 
7 
 
Cherraan’s College of Pharmacy, CBE 
1.2. MODES OF DRUG DELIVERY 
1.2.1 Sustained/Controlled drug delivery 
1.2.2 Targeted drug delivery 
1.2.3 Modulated drug delivery 
1.2.1. SUSTAINED/CONTROLLED DRUG DELIVERY
2
 
 Over past 30 year as the expanse and complication involved in marketing new 
drug entities have increased, with concomitant recognition of the therapeutic advantages 
of controlled drug delivery, greater attention has been focused on development of 
sustained or controlled release drug delivery systems. There are several reasons for the 
attractiveness of these dosage forms. It is generally recognized that for many disease 
states, a substantial number of therapeutically effective compounds already exist. 
 The effectiveness of these drugs, however, is often limited by side effects or the 
necessity to administer the compound in a clinical setting, the goal in designing sustained 
or controlled delivery system is to reduce the frequency of dosing or to increase 
effectiveness of the drug by localization at the site of action reducing the dose required, 
or providing uniform drug delivery.  Sustained release constitutes any dosage form that 
provides medication over an extended time.  Controlled release, however, denotes that 
the system is able to provide some actual therapeutic control, whether this is of a 
temporal nature, spatial nature or both. 
 This correctly suggests that there are sustain release system that cannot be 
considered controlled release system. In general, the goal of a sustained release dosage 
form is to maintain therapeutic blood or tissue levels of drug for an extended period: this 
is usually accomplished by attempting to obtain zero order release from the dosage form.  
Sustained release systems generally do not attain this type of release and provides drug in 
a slow first order fashion. In recent year sustained release dosage forms continue to draw 
attention in the search for improved patient compliance and decreased incidence of 
adverse drug reactions. Sustained release technology is reliably cow field and as a 
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consequence, research in the field has been extremely fertile and has produced many 
discoveries.  New and more sophisticated controlled release, sustained release delivery 
system are constantly being developed and tested. 
 Sustained release, sustained action, prolonged action, controlled release, extended 
action, timed release, depot and repository dosage forms terms used to identify drug 
delivery system that are designed to achieve or prolong therapeutic effect by continuously 
releasing medication over an extended period of time after administration of a single 
dose. 
 
Figure 2:Drug level verses time profile showing differences between zero order 
controlled release, slow first order sustained release and release from conventional tablet. 
 Systems that are designed as prolonged release can also be considered as attempts 
at achieving sustained release delivery.  Repeat action tablets are alternative method of 
sustained release in which multiple doses of drugs are contained within a dosage form, 
and each dosage is related to periodic interval. Delayed release systems, in contrast may 
not be sustaining, since often function of these dosage forms is to maintain the drug 
within the dosage form for some time before release. Commonly the release rate of drug 
is no altered and does not result in sustained delivery once drug release has begun. 
 Successful fabrication of sustained release products is usually difficult and 
involves consideration of physicochemical properties of drug, pharmacokinetic behavior 
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of drug, route of administration, disease state to be treated and most importantly, 
placement of the drug in dosage form total will provide the desired temporal and spatial 
delivery pattern for the drug. 
 The slow first order obtained by a sustained release pre parathion is generally 
achieved by the release of the drug from a dosage form. In some cases, this achieved by 
making slow release of drug from a dosage form. In some cases, this is accomplished by 
a continuous release process. 
ADVANTAGES AND DISADVANTGES OF ORAL SUSTAINED RELEASE 
SYSTEMS 
ADVANTAGES 
 Avoid patient compliance problems. 
 Employ less total drug. 
 Minimize or eliminate local or systemic side effects. 
 Obtain less potentiation or reduction in activity with chronic use. 
 Minimize drug accumulation with chronic dosing. 
 Improve efficiency in treatment 
 Cure or control condition more promptly. 
 Improve control of condition (reduce fluctuation in drug level) 
 Make use of special effects.(e.g. SR Aspirin for morning relief of 
arthritis by dosing before bed time) 
 Improved treatment of chronic illness (e.g. Asthma) 
 Maintenance of therapeutic action overnight. (e.g. Overnight management 
of pain) 
 Reduction in amount of drug taken over a period of drug administration. 
DISADVANTAGES 
 High cost. 
 Poor in-vitro/in-vivo correleation. 
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 Reduced potential for dose change or withdrawal in the event of allergy or 
poisoning. 
 Over dose or dose dumping. 
 Loss of flexibility in dosage. 
Rationale of Sustained Drug Delivery  
              The basic rationale for sustained drug delivery is to alter the pharmacokinetic 
and pharmacodynamics of pharmacologically active moieties by using novel drug 
delivery systems or by modifying the molecular structure and / or physiological 
parameters inherent in a selected route of administration. It is desirable that the duration 
of drug action become more important to design properly. 
 As mentioned earlier, primary objectives of controlled/sustained drug delivery are 
to ensure safety and to improve efficiency of drugs as well as patient compliance.  This 
achieved by better control of plasma drug levels and frequent dosing. For conventional 
dosage forms, only the dose (D) and dosing interval (C) can vary and, for each drug there 
exists a therapeutic window of plasma concentration, below which therapeutic effect is 
insufficient, and above which toxic side effects are elicited. This is often defined as the 
ration of median lethal dose (LD 50) median effective dose (ED 50) 
Factors Affecting Sustained Release Dosage Forms: 
Physicochemical properties of drug. 
 Dose size 
 If an oral product has a dose size greater that 0.5 gm it is a poor candidate for 
sustained release system. Since addition of sustaining dose and possibly the sustaining 
mechanism will, in most cases generates a substantial volume product that unacceptable 
large. 
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 Aqueous solubility 
 Most of drugs are weak acids or bases, since the unchanged form of a drug 
preferentially permeates across lipid membranes.  Aqueous solubility will generally be 
decreased by conversion to an unchanged form for drugs with low mechanism. The lower 
limit on solubility for such product has been reported .1mg/ml drugs with great water 
solubility are equally difficult to incorporate into sustained release system. Ph dependent 
solubility, particularly in the physiological pH range, would be another problem because 
of the variation in pH throughout the GI tract and hence variation in dissolution rate. 
 Partition coefficient 
 Partition coefficient is generally defined as the fraction of drug in an oil phase to 
that of an adjacent aqueous phase.  Accordingly compounds with relatively high partition 
coefficient are predominantly lipid soluble and consequently have very low aqueous 
solubility. Compounds with very low partition coefficients will have difficulty in 
penetrating membranes resulting poor bioavailability 
 Pka 
 The relationship between Pka of compound and absorptive environment, 
presenting drug in an unchanged form is adventitious for drug permeation but solubility 
decrease as the drug is in unchanged form. 
 Drug stability 
 Orally administered drugs can be subject to both acid base hydrolysis and 
enzymatic degradation.  Degradation will proceed at the reduced rate for drugs in the 
solid state, for drugs that are unstable in stomach: system that prolong delivery ever the 
entire course of transiting tried are beneficial.  Compounds that are unstable in the small 
intestine any demonstrate decreased bioavailability when administered from a sustaining 
dosage from. This is because more dug is delivered in small intestine and hence subject to 
degradation. 
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 Molecular size and diffusivity 
 The ability of drug diffuse through membranes is so called diffusivity and 
diffusion coefficient is function of molecular size (or molecular weight) 
 Generally, values of diffusion coefficient for intermediate molecular weight 
drugs, through flexible polymer range from 10-8 being most common for drugs with 
molecular weight greater than 500, the diffusion coefficient in many polymers frequently 
are so small that they are difficult to quantify i.e. less than 16-12 cm
2
 /sec. thus high 
molecular weight drugs and/ or polymeric drugs should be expected to display very slow 
release kinetics in sustained release device using diffusion through polymer membrane. 
 Protein binding 
      It is well know that many drugs bind to plasma protein with a concomitant 
influence on the duration of drug action. Since blood proteins are for the most part re-
circulate and not eliminated, drug.  Protein binding can serve as a depot for drug 
production a prolonged release profile, especially if a high degree of drug binding occurs. 
      Extensive binding to plasma proteins will be evidence by a long half life of 
elimination for drugs and such drugs generally most require a sustained release dosage 
form. However, drugs that exhibit height degree of binding to plasma proteins also might 
bind to bio-polymers in GI tract which could have influence on sustained drug delivery. 
The presence of hydrophobic moiety on drug molecule also increases the binding 
potential. 
Biological factors 
 Biological half life 
 The usual goal of an oral sustained release product is to maintain therapeutic 
blood levels over an extended period. To action this, drug must enter in the circulation of 
approximately the same rate of which it is eliminated. The elimination rate is 
quantitatively described by half-life (t1/2).  Therapeutic compounds with short half lives 
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are excellent candidates for sustained release preparations, since this can reduce dosing 
frequency. In general drugs with half-lives shorter than 3 hours are poor candidates for 
sustained release dosage forms because dose size will increase.  Compounds with long 
half lives, more than 8 hours are also not used in sustained release forms because their 
effect is already sustained. 
 Absorption 
 The rate, extent and uniformity of absorption of a drug are important factors 
when consider its formulation into a sustained release system.  As the rate limiting step in 
drug delivery from a sustained-release system is its release from a dosage form, rather 
than absorption. Rapid rate of absorption of drug, relative to its release is essential if the 
system is to be successful. If we assume that transit time of drug must in the absorptive 
areas of the GI tract is about 8- 12 hours. The maximum half life for absorption should be 
approximately 3-4 hours; otherwise device will pass out of potential absorption regions 
before drug release is complete. 
 Distribution 
 The distribution of drugs into tissues can be important factor in the overall drug 
elimination kinetics. Since it not only lowers the concentration of circulating drug but it 
also can be rate limiting in its equilibrium with blood and extra vascular tissue, 
consequently apparent volume of distribution assumes different values depending on time 
course of drug disposition. For design of sustained/controlled release products. One must 
have information of disposition of drug. 
 Metabolism 
 Drugs that are significantly metabolized before absorption, either in lumen or 
the tissue of the intestine, can show decreased bioavailability form slower-releasing 
dosage forms.  Most intestinal wall enzymes systems are saturable. As drug is released at 
a slower rate to these regions, less total drug is presented to the enzymatic. Process 
device a specific period, allowing more complete conversion of the drug to its metabolite. 
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Strategies and Design of oral controlled release systems
5
 
  The Design and fabrication of oral controlled release systems is reviewed 
under the following classification 
I. Continuous Release Systems  
 Dissolution Controlled release systems 
Matrix Type 
Reservoir Type 
 Diffusion Controlled release systems 
 Matrix Type 
 Reservoir Type 
 Dissolution and diffusion controlled release systems.  
 Ion-Exchange Systems. 
 Slow dissolving salts and complexes. 
 pH dependent formulations. 
 Osmotic pressure controlled release systems. 
 Hydrodynamic pressure controlled release systems. 
 
II.  Delayed Transit and Continuous release systems 
 Altered density systems. 
 Mucoadhesive systems. 
 Size-based systems. 
III. Delayed release systems 
 Intestinal release systems 
 Colonic release systems. 
CRITERIA FOR EVALUTING ORAL CONTROLLED RELEASE SYTEMS 
  The ultimate criteria for evaluating such dosage forms are the amount of drug 
intended to be absorbed is indeed absorbed in a predictable and consistent manner 
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  The steady state ratio of maximum to minimum drug concentration is 
optimally less than that produced by a more frequently administered conventional dosage 
form. 
 In a simplest model, the fate of drug may be characterized by a single 
compartment which is described by figure given below: 
 
Figure 3: A simple pharmacokinetic model. 
DRUGS SUITABLE FOR SUSTAINED RELEASE FORMULATION
6
 
 Not all the drug tend themselves to the formulation of sustained release 
product.  The important factors that are to be considered in choice of a drug as candidate 
of SR preparation are as follows: 
Biological half life 
 The pharmacological effect of some drugs with short half-lives is sustained by 
various mechanisms. 
 The drug binds to the tissues. E.g., tissue bound ace inhibitors. for these drugs, 
less frequent dosing is needed even though the drug is having short half-lives 
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 The drugs with very short half-lives that is, less than two hours are poor candidate 
for SR preparation, because large quantities of drug required for such a 
formulation. 
 The relationship between response and plasma/blood concentration is relative 
concentrations which are in the plateau region of dose response relationship E.g. 
Thiazides in hypertension. 
 The drug is metabolized to pharmacological active metabolites which are more 
slowly cleared than the parent drug. E.g. quinapril, trandolapril, venlafaxine. 
Therapeutic range 
 Drugs that are highly potent such as cardiac glycosides should not be 
considered for SR/CR preparation due to loss in flexibility in dosage regimen and 
potential sudden dose dumping. 
 Drug concentration level in blood is not necessarily equal to the quantity of the 
released from a device because drug absorption is determined largely by its solubility and 
availability of local blood flow in tissues. 
 Even if drug concentration in plasma were to remain reasonably constant, short 
term fluctuations will always be seen due to factors like physical activities, emotional 
situations (stress), eating, and sleeping. 
1.2.2  TARGETED DRUG DELIVERY 
9
 
 Targeted drug delivery refers to systemic administration of drug carrier to 
deliver it to specific cell types, tissues, or organs. 
o RATIONALE FOR TARGETED DRUG DELIVERY 
  Targeting is intended to increase the specific distribution of drug and hence 
combined with lower dosing, to increase the therapeutic profile of a compound. 
Introduction 
 
17 
 
Cherraan’s College of Pharmacy, CBE 
 Most drug after administration in a conventional immediate or controlled 
release dosage form freely travel throughout the body, typically leading to uptake by 
cells, tissues or organs other than where their pharmacological receptors are located. 
REASONS FOR SITE-SPECIFIC DELIVERY OF DRUGS 
 Pharmaceutical 
 Drug instability and drug solubility. 
Biopharmaceutical 
 Low absorption  
 High membrane binding 
 Biological instability 
Pharmacokinetics 
 Short half-life 
 Large volume of distribution 
 Low specificity 
Clinical  
 Low therapeutical index 
 Anatomical or cellular barriers 
Commercial  
 Drug presentation (dosage form) 
Types of drug release from particle carriers: 
 The drug release from the particle carries may be mainly based on 
physicochemical factors, but biological factors can influence drug release. 
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 The release may be based on the following principle 
 Diffusion 
 Iron exchange involving particle diffusion and leasching 
 Surface erosion 
 Total sphere disintegration due to enzyme attack. 
 Control of membrane permeability by use of either pH , heat, microwave or 
magnetic property 
1.2.3.MODULATED DRUG DELIVERY  
 Modulated release implies a drug delivery device that release the drug at a 
variable rate controlled by 
 Environmental conditions 
 Bio feed back 
 Sensor input 
 External control device. 
1.3.MICROPARTICLE
7,8
 
 A well designed controlled drug delivery system can overcome some of the 
problems of conventional therapy and enhance the therapeutic efficacy of a given drug. 
To obtain maximum therapeutic efficacy, it becomes necessary to deliver the agent to the 
target tissue in the optimal amount in the right period of time there by causing little 
toxicity and minimal side effects. 
 There are various approaches in delivering a therapeutic substance to the target 
site in a sustained controlled release fashion. One such approach is using microsphere as 
carriers for drugs. 
  The microparticulate delivery systems are considered and accepted as a 
reliable means to deliver the drug to the target site with specificity, if modified, and to 
maintain the desired concentration at the site of interest without untoward effects. 
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 Microsphere are characteristically free flowing powders and received much 
attention not only  for prolonged release, but also for targeting of anticancer drug to the 
tumour. In future by combining various other strategies, microspheres will find the 
central place in novel drug delivery, particularly in diseased cell sorting, diagnostics gene 
and genetic material, safe, targeted and effective in vivo delivery and supplements as 
miniature Versions of diseased organ and tissues in the body. 
1.3.1. POLYMER EMPLOYED AS MICROSPHERES 
Microsphere used usually are polymers.  
They are classified into two types: 
1. Synthetic polymers 
2. Natural polymers 
SYNTHETIC POLYMERS 
 Poly methyl methacrylate  
 Poly methyl methacrylate copolymer 
 Poly methyl cyanoacrylate 
 Poly isobutyl cyanoacrylate 
 Poly hexyl cyanoacrylate 
 Poly acrylamide  
 Poly (Na, N-L- lysinediylterephthalamide) 
 Poly D, L-lactide 
 Poly  acryl dextran 
 Poly acryl starch 
 Poly lactic acid 
 Poly lactic acid-poly glycolic acid copolymers 
 Ethyl cellulose 
 Eudragit RL 
 Eudragit RS 
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NATURAL POLYMERS 
 Albumin 
 Gelatin 
 Collagen 
 Agarose 
 Carrageenan 
 Chitosan  
 Starch  
 Poly dextran 
 Poly starch 
PREREQUISITES FOR IDEAL MICROPARTICULATE CARRIERS 
 The material utilized for the preparation of microparticulates should ideally 
fulfill the following prerequisites: 
 Longer duration of action  
 Control of content release of therapeutic efficacy 
 Protection of drug  
  Reduction of toxicity 
  Biocompatibility  
 Sterilizability 
 Relative stability 
 Water solubility or dispersability 
 Bioresorbability 
 Targetability 
 Polyvalent 
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1.3.2. METHODS OF PREPARATION
8,12 
Preparation of microsphere should satisfy certain criteria: 
 The ability to incorporate reasonably high concentrations of the drug. 
 Stability of the preparation after synthesis with a clinically acceptable 
shelf life.  Controlled particle size and dispersability in aqueous vehicle 
for injection. 
 Release of active reagent with a good control over a wide time scale. 
 Biocompatibility with a controllable biodegradability and susceptibility to 
chemical modification. 
1.  SINGLE EMULSION TECHNIQUE 
 The micro particulate carriers of natural polymers i.e. those of proteins and 
carbohydrates are prepared by single emulsion technique. The natural polymers are 
dissolved or dispersed in aqueous medium followed by dispersion in non-aqueous 
medium like oil.  Next cross linking of the dispersed globule is carried out. The cross 
linking can be achieved either by means of heat or by using the chemical cross linkers. 
 The chemical cross linking agents used are glutaraldehyde, formaldehyde, di 
acid chloride etc. heat denaturation is not suitable for thermolabile substance. Chemical 
cross linking suffers the disadvantages of excessive exposure of active ingredient to 
chemicals if added at the time of preparation and then subjected to centrifugation, 
washing, separation 
2. DOUBLE EMULSION TECHNIQUE 
 Double emulsion method of microspheres preparation involves the formation 
of the multiple emulsions or the double emulsion of type w/o/w and is best suited to 
water soluble drugs, peptides, proteins and the vaccines. This method can be used with 
both the natural as well as synthetic polymers. 
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 The aqueous protein solution is dispersed in a lipophilic organic continuous 
phase. This protein solution may contain the active constituents.  The continuous phase is 
generally consisted of the polymer solution that eventually encapsulates of the protein 
contained in dispersed aqueous phase. The primary emulsion is subjected then to the 
homogenization or the sonication before addition to the aqueous solution of the poly 
vinyl alcohol (PVP). This result in the formation of a double emulsion. 
 The emulsion is then subjected to solvent removal either by solvent 
evaporation or by solvent extraction. 
3. POLYMERIZATION TECHNIQUES: 
 The polymerization techniques conventionally used for the preparation of the 
microspheres are mainly classified as: 
 Normal polymerization 
 Interfacial polymerization 
Both are carried out in liquid phase 
Normal polymerization 
 It is carried out using different techniques as bulk, suspension, precipitation, 
emulsion and micellar polymerization processes. 
 In bulk, a monomer or a mixture of monomers along with the initiator 
or catalyst is usually heated to initiate polymerization. Polymer so 
obtained may be moulded as microspheres. Drug loading may be done 
during the process of polymerization. 
 Suspension polymerization also referred as bead or pearl 
polymerization. Here it is carried out by heating the monomer or 
mixture of monomers as droplets dispersion in a continuous aqueous 
phase. The droplets may also contain an initiator and other additives. 
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 Emulsion polymerization differs from suspension polymerization as 
due to the presence of initiator in the aqueous phase, which later on 
diffuses to the surface of micelles. 
 Bulk polymerization has an advantage of formation of pure polymers. 
Interfacial polymerization; 
 It involves the reaction of various monomers at the interface between the two 
immiscible liquid phases to form a film of polymer that essentially envelops the dispersed 
phase. 
4. PHASE SEPARATION COACERVATION TECHNIQUE 
 This process is based on the principle of decreasing the solubility of the 
polymer in organic phase to affect the formation of polymer rich phase called the 
coacervates.  In this method, the drug particles are dispersed in a solution of the polymer 
and an incompatible polymer is added to the system which makes first polymer to phase 
separate and engulf the drug particles. Addition of nonsolvent results in the solidification 
of polymer. 
 The process variables are very important since the rate of achieving the 
coacervates determines the distribution of the polymer film, the particle size and 
agglomeration of the formed particles.  The agglomeration must be avoided by stirring 
the suspension using a suitable speed stirrer since as the process of microspheres 
formation begins the formed polymerizes globules start to stick and form the 
agglomerates. Therefore the process variables are critical as they control the kinetic of the 
formed particle since there is no defined state of equilibrium attainment. 
5. SPARY DRYING AND SPARY CONGEALING : 
 These methods are based on the drying of the mist of the polymer and drug in 
the air. Depending upon then removal of the solvent or cooling of the solution, the two 
processes are named spray drying and spray congealing respectively. 
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 The polymer is firs dissolved in a suitable volatile organic solvent such as 
dichloromethane, acetone, etc. the drug in the solid form is then dispersed in the polymer 
solution under high speed homogenization. This dispersion is the atomized in a stream of 
hot air. The atomization leads to the formation of the small droplets or the fine mist from 
which the solvent evaporates instantaneously leading the formation of the microspheres 
in a size range 1-100 µm. 
 Microparticles are separated from the hot air by means of the cyclone separator 
while the traces of solvent are removed by vacuum drying. One of the major advantages 
of the process is feasibility of operation under aseptic conditions. The spray drying 
process is used to encapsulate various penicillins.  Very rapid solvent evaporation, 
however leads to the formation of porous microparticles. 
6. SOLVENT EVAPORATION: 
  Solvent evaporate method is widely used for the preparation of micro 
particles, involvers removal of the organic phase by evaporation of microparticles, 
involves removal of the organic phase by evaporation of the organic solvent. In this 
method, polymer is dissolved in organic solvent, and then the drug is either dissolved or 
dispersed in the polymer solution. Then the polymer-drug mixture is dispersed in liquid 
manufacturing vehicle phase with agitation to obtain appropriate sized microspheres. 
 The process variables include rate of evaporation of solvent, temperature 
cycles and agitation rates. Choice of vehicle phase and selection of solvent greatly 
influence the properties. 
DRUG LOADING AND DRUG RELEASING KINETICS  
Drug loading 
The active components are loaded over the microspheres principally using two methods, 
o During the preparation of the microspheres 
   or 
o After the formation of the microspheres by incubating the with the drug protein. 
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The active component can be loaded by means of  
 Physical entrapment 
 Chemical linkage 
 Surface adsorption 
The entrapment largely depends on  
  Method of preparation  
  Nature of the drug or polymer (monomer if used) 
  Maximum loading can be achieved by incorporating the drug during the time 
of preparation but it may get affected by many other process variables such as method of 
preparation, presence of additives (e.g. cross linking agent, surfactant stabilizers, etc) heat 
of polymerization, agitation intensity etc. 
DRUG RELEASE 
 Release of the active constituent is an important consideration in case of 
microspheres. The release profile from the microspheres depends on the nature of the 
polymer used in the preparation as well as on the nature of the active drug. The release of 
drug from both biodegradable as well as non-biodegradable microspheres is influenced 
by structure or micro-morphology of the carrier and the properties. 
 Many theoretically possible mechanisms may be considered for the release of 
drug from the microparticulates.  
 Liberation due to polymer erosion or degradation 
 Self diffusion through the pore  
 Release from the surface  of the polymer  
 Pulsed delivery initiated by the application of an oscillating or sonic field. 
Introduction 
 
26 
 
Cherraan’s College of Pharmacy, CBE 
 The drugs could be released through the microspheres by any of the three 
methods Osmotically driven burst mechanism Pore diffusion mechanism Erosion or the 
degradation of the polymer 
 In osmotically driven burst mechanism, water diffuse into the core through 
biodegradable or non-biodegradable coating, creating sufficient pressure that ruptures the 
membrane. The burst effect is main controlled by three factors the 
macromolecule/polymer ratio, particle size of the dispersed macromolecule and the 
particle size of the microspheres. 
 The pore diffusion method is named so because as penetrating water front 
continue to diffuse towards the core. 
 The polymer erosion, i.e. loss of polymer is accompanied by accumulation of 
the monomer in the release medium. The erosion of the polymer begins with the changes 
in the microstructure of the carrier as water penetrates within it leading to the 
plasticization of the matrix 
FACTORS AFFECTING DRUG RELELASE FROM THE PARTICULATE 
SYSTEM 
 DRUG 
o Position in microspheres 
o Molecular weight 
o Physicochemical properties  
o Concentration  
o Interaction with matrix 
 MICROSPHERES 
o Type and amount of matrix poly 
o Size and density of the microspheres 
o Extent of cross linking, denaturation or polymerization Adjuvants 
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 ENVIRONMENT  
o pH 
o polarity 
o presence of enzyme 
 Drug  release from the non-biodegradable type of polymers can be understood 
by considering the geometry of the carrier.  The geometry of the carrier, i.e. whether it is 
reservoir type where the drug is present as a core, or matrix type in which the drug is 
dispersed throughout the carrier, governs overall release profile of the drug or active 
ingredients. 
Matrix type system 
 Release profile of the drug from the matrix type of the device critically 
depends on the state of the dug whether it is dissolved or dispersed in the polymer matrix. 
 In case of the drug dissolved in the polymeric matrix, the amount of drug and 
the nature of the polymer affect the release profile. 
 
   
Figure 4: monolithic device and typical plot of drug release rate vs. time 
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Reservoir type system 
 Drug release from the reservoir type system with rate controlling membrane 
proceeds by first penetration of water through the membrane followed by dissolution of 
the drug in the penetrating dissolution fluid. The dissolved drug after partitioning through 
the membrane diffuses across the stagnant diffusion layer. 
 
Figure 5: Reservoir device and typical plot of drug release rate Vs time 
ADVANTAGES 
 Reliable means of deliver the drug to the target site with specificity, if 
modified, and to maintain the desired concentration at the site of interest without 
untoward effects. 
 Solid biodegradable microspheres have the potential throughout the particle 
matrix for the controlled release of drug. 
 Solid biodegradable microspheres have the potential throughout the particle 
matrix for the controlled release of drug. 
  Microspheres received much attention not only for prolonged release, but also 
for targeting of anticancer drugs to the tumor. 
 The size, surface charge and surface hydrophilicity of microspheres have been 
found to be important in determining the fate of particles invivo. 
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 Studies on the macrophage uptake of microspheres have demonstrated their 
potential in targeting drugs to pathogens residing intracellularly. 
 Blood flow determination: Relatively large microspheres (10-15 µm in Dm) 
are useful for regional blood flow studies in tissues and organs. 
1.4. APPLICATIONS 
1. Microspheres in vaccine delivery 
 The prerequisite of a vaccine is protection against the micro organism or its 
toxic product. An ideal vaccine must fulfill the required of efficacy, safety, convenience 
in application and cost.  Biodegradable delivery systems for vaccines that are given by 
parenteral rout may overcome the shortcoming of the conventional vaccine. 
Microspheres as a carrier offer specific advances including: 
 Improved antigenicity by adjuvant action 
 Modulation of antigen release 
 Stabilization of antigen 
2. Targeting using microparticulate carriers 
 The concept of targeting i.e. site specific drug delivery is a well established 
dogma, which is gaining full attention. Placement of the particles indiscrete anatomical 
compartment leads their retention either because of the physical properties of the 
environment of biophysical interaction of the particles with the cellular content of the 
target tissue. 
3. Monoclonal antibodies mediated microspheres targeting 
 Monoclonal antibodies targeting microspheres are immunomicrospheres. This 
targeting is a method used to achieve selective targeting to the specific sites.  Monoclonal 
antibodies are extremely specific molecules. This extreme specificity of monoclonal 
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antibodies (Mabs) can be utilized to target microspheres loaded bioactive molecules to 
selected sites.  
The Mabs can be attached to microspheres by any o f the following methods 
 Non specific adsorption  
 Specific adsorption  
 Direct coupling  
 Coupling via reagents 
4. Chemoembolisation 
 Chemoembilisation is an endovascular therapy, which involves the selective 
arterial embilisation of a tumour together with simultaneous or subsequent local delivery 
the chemotherapeutic agent the theoretical advantage is that such embolisations will not 
only provide vascularocclusion but will bring about sustained therapeutic levels of 
chemotherapeutics in the areas of the tumour. 
5.Imaging 
 The microspheres have been extensively studied and used for the targeting 
purposes.  Various cells, cell lines, tissues and organs can be imaged using radio labeled 
microspheres. The particle size range of microspheres is an important factor in 
determining the imaging of particular sites. 
6. Topical porous  microspheres 
 Microsphonges are porous microsphere having myriad of interconnected voids 
of particle size range 5-300 µm. these microsponges having capacity to entrap wide range 
of active ingredients such as emollients fragrances, essential oils., are used as the topical 
carries system 
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7. Surface modified microsphere 
 Different approaches have been utilized to change the surface properties of 
carriers to protect them against phagocytic clearance and to alter their body distribution 
patterns. The adsorption of the poloxamer on the surface of the polystyrene, polyester or 
poly methyl methacrylate microspheres renders them more hydrophilic and hence 
decreases their MPS uptake. Protein microspheres covalently modified by PEG 
derivatives show decreased immunogenicity and clearance. 
The most studied surface modifiers are : 
 Antibodies and their fragments 
 Proteins  
 Mono-oligo- and polysaccharides 
 Chelating compounds (EDTA, DTPA OR Desferroxamine) 
1.5. PHYSICOCHEMICAL EVALUATION 
CHARACTERIZATION 
 The characterization of the microparticulate carrier is an important 
phenomenon, which helps to design a suitable carrier for the proteins, drug or antigen 
delivery. These microspheres have different microstructures. These microstructures 
determine the release and the stability of the carrier. 
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Table 1: METHODS FOR CHARACTERIZATION OF MICROSPHERES 
SI.No Parameter Method 
1. Particle size and shape Light microscopy (LM) 
Scanning electron microscopy (SEM) 
Conflocal fluorescence microscopy 
Laser light scattering  
Multi size coulte counter 
2. Surface elemental analysis Electron spectroscopy 
ATRFT-IR 
3. Density  Helium compression pychnometry 
4. Crystallinity x-ray diffraction 
differential Scanning  calorimetry 
5. Surface charges  Electrophoresis 
Laser Doppler anemometry 
6. Hydrophobicity Hydrophobic interaction 
chromatography  
Angle of contact measurement 
7. Molecular weight Gel chromatograpy 
8. Invitro methods Beaker method  
Interface diffusion method 
USP dissolution apparatus 
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1.6. ROUTES OF ADMINISTRATION OF MICROSPHERES 
 Microspheres can be administered through different routes such as oral, 
parentral, ocular etc. 
Peroral administration 
 Microspheres can be designed for controlled release to the GI tract, the release 
of drug depend on the size of microparticles and the drug content within the 
microspheres. Microspheres of mucoadhesive polymer get attached to the mucus layerin 
GIT and hence prolong the gastric residence time and functionally offer a sustained drug 
release. 
Parentral administration  
 Microspheres given by intravenous route distribute themselves according to 
their size range. The microparticulate carriers are rapidly cleared from the circulation 
mainly by means of RES system. 
Ocular  
 Microparticulate system is a novel approach to increase the retention time of 
drug delivery device by changing them to gel form in the cul de sac of the eye. 
Intranasal 
 Intranasal route is exploited for the delivery of peptides and proteins. The 
conventional dosage forms are rapidly cleared from the nasal mucosa. 
Bioadhesivemicrosphere have greater control over the surface character and the release 
pattern. 
1.7. HYPERTENSION
11,12
 
 Hypertension is a chronic medical condition in which the blood pressure is 
elevated. It is also referred to as high blood pressure or shortened to HT, HTN or HPN. 
The word “hypertension”, by itself, normally refers to systemic, arterial hypertension. 
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 Hypertension can be classified as either essential (primary) or secondary, 
Essential or primary hypertension means that no medical cause can be found to explain 
the raised blood pressure.  It is common. About 90-95% of hypertension is essential 
hypertension.  Secondary hypertension indicates that the high blood pressure is a result of 
(i.e., secondary to) another condition, such as kidney disease or tumours (adrenal 
adenoma or pheochromocytoma). 
 Persistent hypertension is one of the risk factors for strokes, heart attacks, heart 
failure and arterial aneurysm, and is a leading cause of chronic renal failure.  Even 
moderate elevation of arterial blood pressure leads to shortened life expectancy.  At 
severely high pressures, defined as mean arterial pressures 50% or more above average, a 
person can expect to live no more than a few years unless appropriately treated.  
Beginning at a systolic pressure (which is peak pressure in the arteries, which occurs near 
the end of the cardiac cycle when the ventricles are contracting) of 115 mmHg and 
diastolic pressure (which is minimum pressure in the arteries, which occurs near the 
beginning of the cardiac cycle when the ventricles are filled with blood) of 75 mmHg 
(commonly written as 115/75 mmHg), cardiovascular disease (CVD) risk doubles for 
each increment of 20/10 mmhg. 
. 
 
Figure 6: The variation in pressure in the left ventricle (blue line) and the aorta (red line) 
over two cardiac cycles (“heart beat”), showing the definitions of systolic and diastolic 
pressure. 
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 A recent classification recommends blood pressure criteria for defining normal 
blood pressure, prehypertension, hypertension (stages I and II), and isolated systolic 
hypertension, which is a common occurrence among the elderly. These readings are 
based on the average of seated blood pressure readings that were properly measured 
during 2 or more office visits. In individuals older than 50 years, hypertension is 
considered to be present 90 mmHg diastolic.  Patients with blood pressures over 130/80 
mmHg along with Type 1 or Type 2 diabetes, or kidney disease require further treatment. 
Table 2: Classification of hypertensions 
Classification 
Systolic pressure Diastolic pressure 
mmHg 
kPa 
(kN/m
2
) 
mmHg 
kPa 
(kN/m
2
) 
Normal 90-119 12-15.9 60-79 8.0-10.5 
prehypertension 120-139 16.0-18.5 80-89 10.7-11.9 
Stage 1 140-159 18.7-21.2 90-99 12.0-13.2 
Stage 2 =160 =21.3 =100 =13.3 
Isolated systolic 
hypertension 
=140 =18.7 <90 <12.0 
 
 Resistant hypertension is defined as the failure to reduce blood pressure to the 
appropriate level after taking a three-drug regimen (include thiazide diuretic) 
 Excessive elevation in blood pressure during exercise is called exercise 
hypertension. The upper normal systolic values during exercise reach levels between 200 
and 230 mmHg. Exercise hypertension may be regarded as a precursor to established 
hypertension at rest. 
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SIGNS AND SYMPTOMS 
 Mild to moderate essential hypertension is greatly asymptomatic. Accelerated 
hypertension is associated with headache, somnolence, confusion, visual disturbances, 
and nausea and vomiting (hypertensive encephalopathy).  Retinas are affected with 
narrowing of arterial diameter to less than 50% of venous diameter, copper or silver wire 
appearance, exudates, hemorrhages, or papilledema. Some signs and symptoms are 
especially important in infants and neonates such as failure to thrive, seizure, irritability 
or lethargy, and respiratory distress. While in children hypertension may cause headache, 
fatique, blurred vision, epistaxis, and bell palsy. 
 Sign and symptoms associated with pre-eclampsia and eclampsis, can be 
proteinuria, edema and hallmark of eclampsia which is convulsions, other cerebral signs 
may precede the convulsion such as nausea, vomiting, headaches, and blindness. 
 Initial assessment of the hypertensive patient should include a complete history 
and physical examination to confirm a diagnosis of hypertension.  Most patients with 
hypertension have no specific symptoms referable to their blood pressure elevation. 
elevated arterial pressure, headache. dizziness, palpitations, easy fatigability and 
impotence. 
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Angina pectoris 
40
 
            Angina pectoris, or just angina, is temporary chest pain or discomfort 
caused by decreased blood flow to the heart muscle. Because of the decreased flow of 
blood, there is not enough oxygen to the heart muscle resulting in chest pain. Coronary 
artery disease , which can result in narrowing of the coronary arteries that carry blood and 
oxygen to the heart muscle, is one of the most common causes of angina. While angina is 
not a heart attack, it does signal an increased risk for a heart attack. Seek immediate 
medical attention if you experience any chest pain or discomfort. 
There are two main types of angina 
- stable  
  - unstable. 
 Stable angina, the most common type, develops during physical activity and 
usually lasts a short time (approximately five minutes or less) if the physical activity has 
ended. Unstable angina is less common and usually occurs during periods of rest. 
Unstable angina usually lasts longer and symptoms may be more severe. 
Symptoms of angina include: 
Chest pain or discomfort, such as tightening of the chest 
Discomfort in the jaw, neck, arms, upper abdomen, shoulder or back 
Fatigue, Sweating, Nausea, Dizziness 
Diagnosing and evaluation 
 In order to diagnose the cause of angina, the following tests may be performed: 
 Electrocardiogram (ECG)  
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 Blood tests 
 Chest x-ray   
 CT of the chest  
 Coronary computed tomography (CT) angiography  
 Magnetic resonance (MR) imaging/angiography  
 Catheter angiography  
 Echocardiogram   
 Coronary artery bypass graft surgery (CABG)  
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DRUG PROFILE 
AMLODIPINE BESYLATE 
Chemical formula 
A) 3-Ethyl 5-methyl ?(4RS-2-[(2-aminoethoxy)]-4-(2-chlorophenyl-6-methyl-1,4-
dihydropyridien-3,5-dicariboxtlate benzensulphate. 
OR 
B) 3-ethyl 5-methyl 2-(2-aminomethoxymethyl)-4(chlorophenyl)-q,4-dihydro6-
methylpyridine-3,5-dicarboxylate monobenzenesulphonate. 
 
Chemical structure 
 
 
 
Figure 7: Structure of Amlodipine Besylate 
 
Empirical formula : C26H31CLN2O8S 
Molecular weight : 567.1 
Description  : White or almost white powder 
Melting point  : 195-2040° 
Drug Profile 
 
 
 
40 
 
Cherraan’s College of Pharmacy, CBE 
 
Solubility  : Slightly soluble in water, freely soluble in  
    methanol, sparingly soluble in ethanol, slightly  
    soluble in 2-propanol. 
Therapeutic category: Anti –anginal, 
    Anti-hypertensive 
Half life  : 30 – 35 hours 
 
Mechanism of action:   
 Amlodipine besylate is a calcium channel blocking agent.  It inhibits the influx of 
extracellular calcium across the myocardial and vascular smooth muscle cell membranes.  
The decrease in intracellular calcium inhibits the contractile processes of the myocardial 
smooth muscle cells, causing dilation of the coronary and systemic arteries, increased 
oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased 
systemic blood pressure, and decreased after load.  Another possible mechanism is that 
amlodipine inhibits vascular smooth muscle carbonic anhydrase activity with consecutive 
pH increase which may be involved in intracellular calcium influx through calcium 
channels. 
Pharmacokinetics: 
Absorption: 
 After oral administration of therapeutic doses, amlodipine is well absorbed with 
peak blood levels between 6-12 hour post dose.  Absolute bioavailability has been 
estimated to be between 60 and 80 % 
Distribution: In-vitro studies have shown that approximate 97.5% of circulating   
  amlodipine is bound to plasma proteins. 
Metabolism: Amlodipine is extensively metabolized by the liver to inactive metabolites 
Excretion: 10% of the parent compound and 60% of metabolites excreted in the urine 
Drug Profile 
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Indications: Hypertension and prophylaxis of angina. 
Dosage and administration: 
 Adult recommended starting dose:  5 mg once daily with maximum dose 10 mg 
once daily.  Small, fragile, or elderly patients or patients with hepatic insufficiency may 
be started on 2.5 mg once daily.  Pediatric staring dose: 2.5 mg to 5 mg once daily. 
Side effects: 
 Amlodipine besylate may cause the following side effects.  Most side effects 
are mild or moderate. 
 Headache 
 Swelling of legs or ankles  
 Tiredness, extreme sleepiness  
 Stomach pain, nausea  
 Dizziness 
 Flushing (hot or warm feeling in your face) 
 Arrhythmia (irregular heartbeat) 
 Heart palpitation (very fast heartbeat) 
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EXCIPIENTS PROFILE 
Ethyl cellulose17 
Structural formula 
 
Figure 8: Structure of Ethyl Cellulose 
 
Nonproprietary names 
Bp :  Ethylcellulose 
PhEur : Ethylcellulose 
USP : Ethylcellulose 
Synonyms: 
Aquacoat ECD; Aqualon; Ashacel; E462;Ethocel; Ethylcellulosum; Surelease. 
Chemical name and CAS Registry Number 
Cellulose ethyl ether  
Empirical formula and Molecular weight 
Ethylcellulose is partially ethoxylated. Ethylcellulose with complete ethoxyl 
substitution (DS = 3) isC12H23O(C12H22O5)nC12H23O5 where n can vary to provide a wide 
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variety of molecular weights.  Ethylcellulose, an ethyl ether of cellulose, is a long-chain 
polymer of β-anhydroglucose units joined together by acetal linkage 
Functional category 
 Coating agent 
 Flavouring  agent   
 Tablet filler  
 Viscosity increasing agent 
Applications in pharmaceutical formulation or technology: 
Used in microencapsulation, sustained-release tablet coating, tablet coating, tablet 
granulation 
Description 
Ethylcellulose is a tasteless, free-flowing, white to light tan-colored powder 
Typical properties 
Density (bulk): 0.4/cm3 
Glass transition temperature  129– 133 degree C (26) 
Moisture content: 
 Ethylcelllulose absorbs very little water from humid air or during immersion, and 
that small amount evaporates readily. 
Solubility:   
 Ethylcellulose is practically insoluble in glycerin propylene glycol, and water. 
Ethylcellulose that contains less than 46.5% of ethoxyl groups is freely soluble in 
chloroform, methyl acetate, and tetrahydrofuran, and in mixtures of aromatic 
hydrocarbons with ethanol (95%).  Ethylcellulose that contains not less than 46.5% of 
ethoxy groups is freelysoluble in chloroform, ethanol (95%), ethyl acetate, methanol, and 
toluene.  
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Specific gravity :    1.12-1.15g/cm3 
Viscosity  :  46 cP, 5 % in toluene/ethanol 80:20 
Density  :  1.4 g/ml at 25 ºC lit 
Uses   :          used as thin film coating material for coating paper, vitamin 
    and medical pill and thickeners in cosmetics and in   
    industrial process and also used in food additives. 
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Hydroxyl Propyl Methyl Cellulos 
Structural formula: 
 
 
Figure 9: Structure of HPMC 
 
Chemical name : cellulose hydroxyl propyl methyl ether. 
Molecular mass : OCH2CH (OH) CH3 
Molecular weight : 10,000-1500000 
Melting point  : 190-200°C 
Physical state  : HPMC is an odorless & tasteless or creamy white fibrous or  
      granular powder.  
Solubility: 
 Soluble in cold water, forming a viscous colloidal in soluble in hot water, 
chloroform, ethanol, dichloromethane, mixtures of water &alcohol. 
Incompatibilities: 
 Incompatible with some oxidizing agents, organic ions to form insoluble 
precipitates. 
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Stability and storage conditions: 
 It is a stable, although it is hygroscopic after drying. 
 Stored in well closed container, in a cool & dry place. 
Functional category: 
 Bio adhesive material, coating agent, controlled release agent, film former, 
emulsifier, solubilizing & stabilizing agent, tablet binder, thickening agent. 
Application of pharmaceutical formulation/ Technology 
 It is widely used in oral, ophthalmic, nasal &topical pharmaceutical formulations. 
 Tablet binder in film coating and as a matrix in extended release tablet 
formulations. 
 In liquid orals which is used as a suspending or thickening agent. 
 Lower viscosity grades are used in aqueous film coated solution, while higher 
viscosity grades are used with organic solvent. 
 It is also used in cosmetic and food products.  
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Poly Vinyl Pyrrolidine 
Structural Formula 
 
Figure 10: Structure of Poly Vinyl Pyrolidine 
Nonproprietary Names : BP: Povidone, USP: Povidone 
Synonyms   : E1201, Kollidone, Plasdone, Polyvinylpyrrolidone. 
Chemical name and  
CAS Registry number : 1-ethyenyl-2-pyrrolidinone homopolymer [9003-39-8] 
Emperical formula  
& Molecular weight  : (C6H9NO)n, 2500-3000,000 
Functional category  : Tablet binder, disintegrant, dissolution enhancer,   
       suspending agent. 
Applications in pharmaceutical formulation or technology: 
 Povidone is used in a variety of pharmaceutical formulations, it is primarily used 
in solid dosage forms.  In tableting povidone solutions are used as binders in wet 
granulation process. It is also added to powder blends in the dry form and granulated in 
situ by the addition of water, alcohol, or hydro alcoholic solutions.  0.5 – 5 % 
concentration is used in tablet binder. 
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Description: 
 Povidone occurs as a fine, white to creamy-white coloured, odorless, hygroscopic 
powder. 
Stability & storage condition: 
 Povidone may be stored at a under ordinary without undergoing decomposition or 
degradation.  Since the powder is hygroscopic, it should be stored in a air tight container 
in a cool, dry place. 
Incompatibilities: 
 It is compatible in solution with a wide range inorganic salts, natural & synthetic 
resins & other chemicals 
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Eudragit RS 100 
 
Figure 11: Structure of Eudragit RS 100 
Eudragit RS 100 is copolymer of methacrylic acid estrs containing an amount of 
quarternary ammonium groups between 4.5 – 6.8%. Eudragit RS 100 is insoluble in 
water and digestive juices, but permeable and has pH-independent release profiles. 
Class   : “Ammonio Methacrylate Copolymer Type B” Ph.Eur. 
Molecular weight :  150,000. 
Solubility   :  Miscible with methanol, ethanol and isopropyl alcohol  
    (containing approx.3%water), as well as in acetone,  
    cholorform, ethyl acetate and Methylene chloride in a  
    ration of    1:1 
Viscosity   : Max. 15 mpa.s 
Stability  : stable under ordinary conditions of storage 
Storage  :  protect from warm temperatures and against moisture. 
    Keep in tightly closed containers. 
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Uses   : Time-controlled release of active ingredients . 
    Therapeutically customized release profiles 
Higher patient compliance due to reduced number of doses 
to be taken. 
Applications  : 
1. Simple taste masking through gastric resistance to controlled drug release 
in all section of the intestine insoluble but permeable in digestic fluids. 
2. Eudragit RS 100 polymer with alkaline enable controlled time release of 
the active ingredient by pH- indipendent swelling . 
3. Delayed and sustained drug release. 
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LITERATURE REVIEW 
Swethakallepu, et al.
19
, have been reported a work on the Formulation and evaluation of 
Gastro Retentive Floating Microsphere of Nimodipine, The microsphere was prepared by 
solvent evaporation method. The result of in-vitro dissolution study. Microsphere was 
characterized for their micromeritic properties, floating behavior, entrapment efficiency, 
scanning electron microscopy (SEM), X-ray diffraction, differential scanning 
colorimetry, and in-vitro drug release it showed good flow properties.  Size ranges of 
(90±1.02)-(145±1.34)µm. Microsphere were capable to float for 12 h.  It can be 
concluded that the developed formulation is potential dosage form for nimodipine. 
Joselinjoseph,et al
20
, have been studied the formulation and evaluation of floating 
microsphere of pantoprazole sodium. The floating microsphere of pantoprazole sodium 
wereprepared by solvent evaporation method using HPMC K 15 and ethyl cellulose as 
polymer. Seven different formulations were developed.  The developed floating 
microspheres were evaluated for, percentage yield, particle size, entrapment efficiency, 
in-vitro buoyancy, scanning electron microscopy and drug release.  Results show that as 
the concentration of polymer ethyl cellulose increase it affects the particle size, 
percentage yield, in vitro buoyancy and drug release of microsphere.  The floating 
microsphere of pantoprazole sodium cane successfully designed for controlled drug 
delivery  dosage forms.  
Megha Sharma et al
21
, have reported the formulation, optimization, characterization and 
in-vitroevaluation of floating microsphere of Repaglinide. Drugs that are easily absorbed 
from the gastrointestinal tract (GIT)and having short half life are eliminated quickly from 
blood circulation and need frequent dosing such Repaglinide. Floating microsphere of 
Repaglinide was prepared by using ethylcellulose (EC) alone and in combination with 
HPMC by solvent diffusion-evaporation technique.  Increase in stirring rate slightly 
increases the drug release and was found to be in the range of 70.2-86.3% for EC whereas 
78.6-86.4 for EC:HPMC formulations.  The mechanism of drug release was studied and 
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found to follows first order kinetics. The regression of optimized formulation were found 
to be 0.926 (E6) and 0.955 (H9). 
NavneetGarud et al
22
, have reported the preparation and in-vitro evaluation of 
Metformin Microspheres using Non-Aqueous solvent Evaporation Technique. The effect 
of process variable, viz, drug polymer ration, stirring rate and type of polymer on the 
mean particle size drug entrapment efficiency, yield, drug content. It was observed that as 
the stirring speed increased from 600 to 1800 rpm, microsphere size decreased and hence 
drug release rate increased.  Drug release rte at 1:2 drug:polymer for microspheres 
produced at a stirring rate of 1200 rpm. The formulation exhibited maximum prolonged 
drug release at gastrointestinal pH or atleast 15 h.  
Ramesh Y.,et al
23
, have been prepared and evaluated the floating microspheres with 
Norfloxacin as model drug for prolongation of gastric residence time.  The microspheres 
were prepared by the Non-Aqueous solvent diffusion method using polymers HPMC and 
EC  SEM analysis. In vitro drug release studies were performed and drug release kinetics 
was evaluated using the linear regression method.  Effects of the stirring rate during 
preparation, polymer concentration, solvent composition and dissolution medium on the 
size of microspheres and drug release were also observed.  The prepared microspheres 
exhibited prolonged drug release (10 h) and remained buoyant for > 12 h. the mean 
particle size increased and the drug release rate decreased at higher polymer 
concentration.   
Vinodkumar et al
24
,  have been studied the formulation and evaluation of floating 
microsphere of Ranitidine Hydrochloride. It inhibited histamine stimulation and gastirin 
stimulated acid secretion.  The microspheres of each batch were subjected to various 
physiochemical studies i.e. particle size, bulk density, % yield, % buoyancy, drug 
entrapment efficiency etc. The compatibility of the drug with selected polymers was 
determined by FTIR spectrophotometric studies using FTIR Affinity -1. Thin layer was 
performed and studied comparative to the pure drug and its micro spherical formulations. 
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Mulugeta Fentie., et al
25
,  have been studied the formulation of sustained release 
floating microsphere of furosemide from EC and HPMC polymer blends. Furesemide is a 
potent and commonly used loop diuretic.  It is absorbed largely in the stomach hand 
upper small intestine.  This narrow absorption window is responsible for its low 
bioavailability of about 50 % and variable and erratic absorption.  Microspheres were 
prepared by the solvent evaporation method.  The drug entrapment ranging from 86.2 % 
to 98.4%.    Floating microsphere that effectively sustain the drug release more than 12 h 
and exhibit buoyancy of greater than 77% in 12 h were developed. 
Mazumder.R., et al
26
, have been reported the formulation and evaluation of floating 
microsphere of amlodipine besylate. The floating microsphere were evaluated for size of 
microsphere, entrapment efficiency, swelling index, buoyancy studies and in-vitro release 
studies.  The result indicated the optimized intragastric floating microsphere (F8) 
exhibited 97% release in 8 hrs. While the buoyance lag time was 20 sec and the 
intragastric floating microsphere remain buoyant for 20 hrs.  In vitro drug release kinetics 
evaluated using the linear regression methods was using found to follow the Zero order 
kinetics.  Optimized intragastric floating microsphere showed no significant change  after 
storage at 40°C/75% relative humidity for 1 month. 
SurendranathBetala.,et al
27
, have formulated the metoprolol sustained release 
microspheres.  It was prepared by Ionic-Gelation method. The microspheres were 
evaluated for various characteristics like encapsulation efficiency, percentage yield, 
partial size and the in vitro release for 12 hours. The microspheres were found to be 
discrete, spherical and free-flowing. The microspheres were uniform in size, and the 
microencapsulation efficiency was in the range of 91.7% Microspheres had good 
spherical geometry. 
Avinash Y Kaushik.,et al
28
, have prepared the valsartan floating microspheres and 
studied it’sin-vitro characterization. solvent evaporation emulsification method using two 
polymers ethylcellulose and eudragit in different concentration and two different 
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surfactant poly vinyl alcohol and tween 80.  In-vitro release and stability of formulation 
were also conducted.  The valsartan floating microspheres F4 and F7 formulations 
followed first order kinetics and F8 formulation followedhiguchi drug release kinetics 
with erosion as the dominant mechanisms of drug release. Ethylcellulose with poly vinyl 
alcohol and eudragit with tween 80 were formulations with good physical appearance.  
less concentration of polymers gives uniform floating microspheres in aspect of particle 
size, good floating ability and good flow property. 
SurendranthBetala., et al
29
, have formulated and evaluated the sustained release 
microspheres of propranolol. Microspheres are prepared by Ionic-Gelation method using 
HPC & EC and sodium CMC for sustained release oral sustained dosage form was 
developed. The microspheres were evaluated for various characteristics like 
encapsulation efficiency, percentage yield, percentage size and the In vitro release for 12 
hrs. The  microspheres were found to discrete, spherical, and free-flowing. The 
microspheres were uniform in size, and the microencapsulation efficiency was in the 
range of 52.5-81.7%  microspheres had good spherical geometry. 
Sigimol Joseph et al
30
, describes the preparation of microspheres by solvent evaporation 
followed by in-vitro characterization of microspheres to evaluate the effect of method of 
preparation on physical properties and drug release profile of microspheres. In-vitro drug 
release rate for a microsphere was found to be sustained over 24 hours.   Hence, it can be 
concluded that the Formulation prepared by solvent evaporation method, has potential to 
deliver Losartan potassium in a controlled manner in a regular fashion over extended 
period of time in comparison to all other formulations and can be adopted for a successful 
oral delivery of losartan potassium for safe management of hypertension. 
Sharma Tejal et al
31
, prepared a floating drug delivery system of ranitidine. It was 
prepared by solvent evaporation (oil-in-water emulsion) technique using HPMC and EC 
as the rate controlling polymers.  Particle size analysis, drug entrapment efficiency, 
surface topography, buouancy percentage and release studies were performed.  Result 
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showed that the polymer ratio and stirring speed affected the size, incorporation 
efficiency and drug release of microspheres (>12 h), floating time (>12 h) and the best 
results were obtained at the ratio of HPMC:EC (1:6).  The particle size of microspheres 
increased by the drug release rate from the microspheres decreased as the polymer 
concentration increased. So it is used for prolonged drug release in stomach for at least 12 
hrs. 
ShardenduPrakash et al
32
, was studied the development of floating microsphere of 
Gliclazide in order to achieve and extended retention in the upper gastrointestinal tract,  
The prepared microspheres were evaluated for particle size, micromeritic study, drug 
entrapment efficiency, in vitro buoyancy, swelling index and in vitro release  & good 
flow properties.  SEM confirmed spherical structure of the prepared microspheres.  The 
best formulation F3 drug release kinetics were evaluated using Zero order, First order 
Higuchi model, Korsmeyer – Peppas model. It was observed that the Korsemeyer – 
Peppas model has a higher regression coefficient values indicating that the drug release 
was based on the erosion of polymeric chain matrix. 
Shajijessy et al
33
, was developed the aceclofenac microsphere for floating pulsatile 
release intended for chronopharmacotherapy by emulsion solvent diffusion technique. 
The best batch exhibited a high entrapment efficiency of 90.1 % and mean particle size 
118.66µm. polymers used for the preparation were Eudragit L100 and Eudragit S100 
which gets solubilized at pH above 6 and 7 respectively.  The floating microsphere 
provide two phase patter with initial lag time during floating in acidic medium followed 
by rapid release in phosphate buffer.  This approach suggested the use of floating 
pulsatile microsphere as promising drug delivery for site and time specific release 
fromchronotheraphy of rheumatoid arthritis. 
KaminiVasava et al
34
, was prepared a floating drug delivery system of Cephalexin. By 
emulsion solvent technique.  Particle size analysis, drug encapsulation efficiency, surface 
topography, buoyancy percentage and release studies were performed.  Results showed 
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that the polymer concentration and stirring speed affected the size, incorporation 
efficiency and drug release of microspheres (< 12 h) and its floating time (>12 h). The 
best results were obtained at the ratio of drug:EC (1:6). The mean particle size of 
prepared floating microspheres increased by the drug release rate from the microspheres 
decreased as the polymer concentration increased. Used for prolonged drug release in 
stomach for at least 12 hrs, thereby improving the bioavailability, prevents degradation in 
stomach and patient compliance. 
Kapilkumar and AK Rai et al
35
 were prepared and evaluate floating microspheres of 
curcumin for prolonged gastric residence time and increased drug bioavailability. 
Emulsion solvent method, using HPMC, EC, Eudragit S 100 polymer varying ratio. It 
was evaluated for flow properties, particle size, incorporation efficiency, as well as in-
vitro floatability and drug release.  The shape and surface morphology of the  
microsphere by optical SEM. The floating microspheres showed particle size, buoyancy, 
drug entrapment efficiency and yield in the ranges of 251 – 387 µm, 74.6 – 90.6 % and 
45.5 – 82.0 %, respectively.   Maximum drug release after 20 h was 47.1, 55.7, 69.4 and 
81.3% for formulations F1,F2,F3 and F4, respectively.  SEM  
Swapnila V Shinde (Vanshiv) et al 
36
, were develop the floating microspheres of 
Domperidone  by emulsion solvent diffusion method using HPMC K 4 M, Ethyl 
cellulose.  In-vitro drug release, FT-IR. The yield, particle size, buoyancy percentage, 
drug entrapment efficiency, and  microspheres yielded 62.40 – 89.49 %.  The particle size 
was distributed between 147 – 282.11 µm, Drug entrapment efficiency was 54.4 – 64.48 
%, and Buoyancy percentage was 71 -87%.  The best drug release profiles were seen with 
formulation F1 at the ratio of drug to polymer of, 1:1.. 
M. Najmudiin et al
.37
, was prepared the floating microspheres of ketoprofen using 
Eudragit S 100 and Eudragit L 100 as polymer. Bulk density less than gastric fluids and 
so remains buoyant in the stomach without affecting gastric emptying rate for a 
prolonged period of time.  It was prepared by emulsion solvent diffusion method using 
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Eudragit S 100 and Eudragit L 100 as polymer.  Micromeritic properties, particle size, 
percentage yield, in-vitro buoyancy, incorporation efficiency, drug polymer compatibility 
(IR study), SEM and drug release of microspheres.    Formulation EU2 prepared with 
Eudragit S 100 drug:polymer ratio (1:2) which exhibited excellent micromeritic 
properties, percentage yield, in-vitro buoyancy, incorporation efficiency  and percentage 
drug release 92.26 % for a period of 12 hrs.   
ShankraiahM et al.
38
, studied the development of new intra-gastric floating 
microspheres  by emulsion solvent evaporation technique.  The drug was encapsulated 
with HPMC and Eudragit S 100 in different polymers ratios. i.e. 1:1, 1:2, 1:3 prepared 
microspheres were evaluated for % entrapment, particle size, Buoyancy, dissolution 
study and drug release kinetics.   The % yield of microspheres was high in HPMC 
batches over Eudragit RS 100 batches.  The particle sizes of microspheres was increased 
by increasing the polymer concentration. % buoyancy of microspheres,63.38%-75.58% 
Microspheres of levofloxacin with HPMC showed enhanced release rate when compared 
to levofloxacin with Eudragit S 100.  
Yuveraj Singh et al
39
, were prepared and evaluated the floating microspheres of 
verapamil hydrochloride. Cellulose acetate, acrycoat S100 and eudragit S100 
microspheres loaded with verapamil hydrochloride were prepared by solvent diffusion – 
evaporation method. Smooth surfaces, free-flowing and good-packing properties. The 
yield of was up to 70.51% and cellulose acetate microspheres entrapped the maximum 
amount of the drug.  SEM confirmed their hollow structures with sizes in the range 
251.80 to 350.75 µm. Microspheres exhibited prolonged drug release and remained 
buoyant for more than 12 h.  radiographic images of dog stomach revealed that cellulose 
acetate microspheres loaded with barium sulphate floated on the gastric fluid for about 
3.2 h.  In vitro release studies demonstrated non-fickian diffusion of drug from the 
microspheres.  
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AIM AND SCOPE OF STUDY 
 The purpose of this research work was to develop a novel retentive floating 
microsphere of amlodipine besylate. 
 
 Amlodipine besylate has maximum solubility in acidic pH and thus most suitable 
to prolong release of drug in stomach so an attempt has been made to sustain the 
drug release by incorporation suitable polymers such as ethylcellulose and PVP. 
 
 In the form of gastro retentive floating microspheres which after oral 
administration are designed to provide. The desired controlled and complete 
release of drug for prolonged period of time in the treatment of calcium channel 
block and used in the treatment of hypertension and angina pectoris. The 
maintenance of constant plasma level of a cardiovascular drug is important in 
ensuring the desired therapeutic response.  Amlodipine besylate is used in the 
treatment of several disease of the cardiovascular system, especially hypertension. 
 
 The main aim of the present study is to develop sustained release Amlodipine 
besylate Microsphere using Ethylcellulose , HPMC, PVP, Eudragit RS100 
polymers by solvent evaporation method and to evaluate the suitability and 
potentiality of this sustained release drug delivery system through the 
determination of drug loading capacity, entrapment efficiency, flow properties 
and in-vitro release characteristic studies. 
 
 Amlodipine besylate has half life of 30 to 35 hours. Multiple dosing  needed to 
maintain a constant plasma concentration for a good therapeutic response and to 
improve patient compliance.  This result in the frequent administration of a drug 
with higher dose causes unwanted side effects and dose dumpling.  Microspheres 
are one of the promising drug delivery system to deliver the drug at a controlled 
rate over the period of time. 
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 Among various polymers, ethylcellulose, HPMC, PVP, Eudragit RS 100 are used 
in the formulation. Eudragit RS 100 is water insoluble and widely used as a wall 
material to sustain the drug release; this is due to its biocompatibility, good 
stability, easy of fabrication. 
 
 Among the various method of preparation, solvent evaporation method has gained 
much attention due to its ease of fabrication without compromising the activity of 
the drug. 
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PLAN OF WORK 
I. PREFORMULATION STUDIES 
(i) Determination of solubility profile of Amlodipine besylate. 
(ii)  Compatibility studies (FT-IR) 
II. FORMULATION OF AMLODIPINE BESYLATE FLOATNG 
MICROPARTICLE 
 
III. EVALUATION OF AMLODIPINE BESYLATE FLOATING 
MICROPARTICLE 
 
1. Determination of Percentage yield 
2. Micromertic Properties 
(i) Angle of Repose 
(ii) Bulk Density and Tapped Density 
(iii) Compressibility Index 
(iv) Hausner’s Ratio 
3. Particle Size and Morphology Analysis (SEM) 
4. Swelling Index (%) 
5. Percentage of Drug content/ Drug loading amount (%) 
6. Percentage of Drug entrapment (%) 
7. In-vitro Buoyancy studies 
8. In-vitro Drug Release 
IV. STABILITY STUDIES 
Stability studies for initial and after one month at 40
o 
C+ 2 and 75 % + 5 % RH. 
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MATERIALS AND EQUIPMENTS 
Table 3: MATERIALS 
S.NO CHEMICAL/MATERIAL SOURCE 
1 Amlodipine besylate GIFT SAMPLE, Sai Meera 
Pharma, Chennai. 
2 Ethylcellulose S.D fine chemicals Ltd. 
3 HPMC S.D fine chemicals Ltd. 
4 PVP S.D fine chemicals Ltd. 
5 Eudragit RS 100 S.D fine chemicals Ltd. 
6 Ethanol S.D fine chemicals Ltd. 
7 Sodium lauryl sulphate (0.1%) S.D fine chemicals Ltd. 
8 Dichloromethane S.D fine chemicals Ltd. 
 
 
Table 4: EQUIPMENTS 
 
S.NO 
 
NAME OF THE INSTRUMENT 
 
 
COMPANY 
1 Mechanical stirrer Remi equipment 
2 UV spectrophotometer Jasco V530 
3 Optical microscope Olympus 
4 FT-IR Spectrophotometer Karunya university, coimbatore 
5 Scanning electron microscopy Karunya university, coimbatore 
6 Magnetic stirrer Remi equpiments, Mumbai 
7 Dissolution apparatus Veego , VDA 6DR USP apparatus 
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METHODOLOGY 
I.  PREFORMULATION STUDIES 
a. Solubility Profile 
 Determination of solubility profile of amlodipine besylate.  The solubility profile 
of the selected drug (Amlodipine besylate) was determined. 
 Slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol, 
slightly soluble in 2-propanol. 
b. Fourier transform  Infra-red spectroscopy 
I.R. spectroscopy can be used to investigate and predict any physiochemical 
interactions between difference components in a formulation and therefore it can be 
applied to the selection of suitable chemically compatible excipients. 
 The aim of the present study was to find out the possible interaction between 
selected polymer, ethylcellulose, HPMC, PVP, Eudragit RS 100 and the drug Amlodipine 
besylate and also identify the compatibility between the drug and polymer. 
10 mg of sample and 40 mg of KBr was taken in a mortar and triturated.  A small 
amount of triturated sample was taken into a pellet marker and was compressed at 10 
kg/cm
2
 using hydraulic press.  The pellet was kept in a sample holder and scanned from 
4000 cm-1 in Perkin Elmer FT-IR spectrophotometer. 
Samples were prepared for pure polymer, pure drug, physical mixture of drug and 
polymer and drug loaded microparticles.  The spectra obtained for these samples were 
compared and interpreted for the shifting of major functional peaks and disappearance of 
functional peaks if any. 
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II.    FORMULATION OF AMLODOIPINE BESYLATE FLOATING 
 MICROPARTICLES 
 In this present study, solvent evaporation technique was employed for preparation 
microsphere formulation. Amlodipine besylate microparticles were prepared by 
dissolving polymer ethylcellulose and HPMC in ethanol and dichloromethane. Then the 
drug amlodipine besylate was added to the polymer solution.  The resulting mixture was 
then added drop by drop into 0.1% sodium lauryl sulphate while stirring continuously.  
Stirring rate was constant at 900 rpm and continued for 30 minutes until organic solvent 
evaporated completely. 
 The dispersed drug and polymer were transferred into fine droplets, which 
subsequently solidified into rigid microparticles due to solvent evaporation.  The 
microparticles formed were collected by filtration, and washed 4 to 5 times with distilled 
water and dried at room temperature for 24 hours. 
 Nine batches of drug loaded microparticles were prepared by keeping drug ratio 
constant altering the different polymer with different ratio and formulations code as 
F1,F2,F3,F4,F5,F6,F7,F8,F9. 
S. 
No 
Incredients 
Formulation code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Drug 0.5 g 0.5 g 0.5 g 0.5 g 0.5 g 0.5 g 0.5 g 0.5 g 0.5 g 
2 Ethylcellulose 0.5 g 4 g 0.3g 0.3 0.3 g - 2 g - 1 g 
3 HPMC E 50 0.3g 0.3g 4 g - - 4 g - 1 g - 
4 Chitosan - - - - 2 g 2 g - - - 
5 PVP - - - - - - - 2 g 2 g 
6 Eudragit RS 100 - - - - - - 0.5 g - - 
7 Ethanol 15 ml 15 ml 15 ml 15 ml 15 ml 15 ml 15 ml 15 ml 15 ml 
8 Dichloromethane 15 ml 15 ml 15 ml 15 ml 15 ml 15 ml 15 ml 15 ml 15 ml 
9 Sodium lauryl 
sulphate (0.1%) 
100ml 100ml 100ml 100ml 100ml 100ml 100ml 100ml 100ml 
Table 5: Formulation of Amlodipine Besylate Microparticles 
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III.  PREPARATION OF STANDARD GRAPH OF AMLODIPINE BESYLATE 
 USING PHOSPHATE BUFFER pH 7.4 
Preparation of stock solution 
 10 mg of accurately weighed drug was dissolved and diluted to 100 mil with 
phosphate buffer pH 7.4 to produce 100 µg/ml. 
Preparation of sample solution 
 Different dilutions of stock solution with phosphate buffer were made to obtain 
solution having concentration 5,10,15,20,25,30 µg/ml.  absorbance was measured at 360 
nm against phosphate buffer pH 7.4 as blank, using UV systronics-2202 
spectrophotometer. 
  A standard curve was plotted with concentration on X-axis and absorbance on Y-
axis. 
IV.  EVALUATION OF AMLODIPINE BESYLATE MICROPARTICLES 
 Actual drug content of microparticles was determined by UV-spectrophotometer 
(systronics-2202) 50 mg equivalent of drug loaded microsphere were dissolved in 
chloroform and extracted with 50 ml of phosphate buffer 7.4 and then analyzed at 360nm 
a. Entrapment efficiency (%) =        Actual drug content 
                                                                 _________________    X 100 
  Theoretical drug content  
Buoyancy test 
Microparticles (0.3g) were spread over the surface of a USP dissolution apparatus 
(type  II)  filled with 900 ml 0.1 mol.  Hcl  containing 0.01 % Tween 80. The medium 
was agitated with a paddle rotating at 100 rpm for 8 hrs. The floating and the settled 
portion of floating microparticles were recoverd separately.  The floating microparticles 
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were dried and weighed. Buoyancy percentage was calculated as the ratio of the mass of 
the floating microparticles that remained flaoting and the total mass of the floating 
microparticles 
                                                            Microparticles remained floating  
 Percentage buoyancy  =              -----------------------------------------    X  100 
                                                        Total mass of floating microparticles  
Drug loading (%)  =                 Actual drug content 
                                                               ____________________ X 100 
                                                              Weight of Microsparticles  
 
Percentage yield (%)  =                        Weight of Microsphere 
                                                           _________________________X 100 
                                                                 Total expected weight of                
                       Drug and polymer 
Particle size and Morphology analysis 
  The particle size of microparticles was determined using optical 
microscopy method.  Approximately 100 microparticles were counted for particle 
size using a calibrated optical microscope  
  Surface morphology of microsphere was determined by Scanning Electron      
Microscope (SEM).  The microparticles were coated uniformly with gold-palladium by 
using Sputter Coater, after fixing the sample in individual stabs. 
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Swelling Index: 
The swelling indexes of the formulated microparticles were performed pH 1.2 and 
phosphate buffer pH 7.4 at 37.5 ± 0.5°C for 8 hours.  Drug loaded microparticles were 
equilibrated in different test tubes and at every one hour interval; microparticles were 
withdrawn filterd transferred into a small beaker and the weighed. 
 The swelling ratio was calculated from the followed expression, 
                                                            Wf – W0 
                 Swelling index    =           --------------    x 100 
                                                                 W0 
        Where, W1 = weight of micro particle observed at every time interval 
                        W0 = initial weight of micro particles.                         
Micromeritic properties 
i.  Angle of repose 
 Flow properties of microsphere were determined by this method.  Angle of repose 
of different formulation was measured according to a fixed funnel standing method. 
 Ɵ   = tan-1 h/r 
 Where Ɵ is angle of repose, r is radius and h is the height 
Angle of repose Flow property 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
Table 6: Relationship between Flow properties and Angle of Repose 
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ii.  Bulk density and Tapped density 
 Bulk and tapped densities were measured by using 10 ml of graduated cylinder.  
The sample was poured in graduated cylinder and tapped mechanically for 100 times, 
then tapped volume was noted down and bulk density and tapped density were calculated. 
iii.  Carr’s index  
 Compressibility Index (CI) or Carr’s index value of microparticles was computed 
according to the following equation: 
Carr’s index(%) =    Tapped density  –    Bulk density 
    __________________________ 
   Tapped density       ×      100 
% Compressibility 
Flowability 
5-15 
Excellent 
12-16 
Good 
18-21 
Fair-passable 
23-35 
Poor 
33-38 
Very poor 
>40 
Very very poor 
Table 7: Relationship between Percentage Compressibility and Flowability 
iv.  Hausner’s ratio 
 Hausner’ratio of microsphere was determined by comparing the tapped density to 
the bulk density using the equation 
       Tapped density 
        Hausner’s ratio =    _____________ 
           Bulk density 
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Hausner’s ratio Flowability 
<1.25 Good 
>1.25 Poor 
1.25-1.5 Very 
 
Table 8: Relationship between Hausner’s ratio and Flowability 
v. In-vitro dissolution study of Amlodipine besylate microsphere 
 Drug release from the microsphere was performed using the rotating basket 
method as specified in USPXXIV. In-vitro release profile was examined in Phosphate 
buffer pH 7.4 from 1- 8 hours. 
 Microparticles equivalent to 100 mg of drug were placed in the basket and the 
medium was maintained at 37°C and was kept at a rotation of 750 rpm.  An aliquot of 10 
ml were withdrawn periodically at intervals of one hour and same volume of fresh 
medium was replaced. 
 The concentration of drug released at time intervals was determined by measuring 
the absorbance at 360nm using UV spectrophotometer. 
vi.  Stability studies 
 The stability studies indicates the significant difference between the release 
patterns of microsphere at 40°C and RH  for one month. 
 The stability studies were carried out at and optimized formulation, i.e, from F9 
forumulation. The formulation was store at (40°C±2°C at 75% RH ± 5 %) for 1 months.    
Sample were withdrawn and retested for drug release and was compare with the 
formulation diffusion profile. 
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OBSERVATION DATA 
S.NO SOLVENT SOLUBILITY 
1 WATER Slightly soluble 
2 2,PROPANOL Slightly soluble 
3 METHANOL Freely soluble 
4 ALCOHOL Sparingly soluble 
 
Table 9: Solubility Profile of Amlodipine Besylate 
 
 
S. No polymer 
Drug: 
polymer 
ratio 
First day 
After one 
week 
After three 
week 
25°C 40°C 25°C 40°C 25°C 40°C 
1 Ethylcellulose 1:1 NC NC NC NC NC NC 
2 HPMC 1:1 NC NC NC NC NC NC 
3 PVP 1:1 NC NC NC NC NC NC 
4 Ethylcellulose 
HPMC 
1:1:1 NC NC NC NC NC NC 
 
Table 10: Physical observation test for drug polymer compatibility studies 
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FOURIER TRANSFORM INFRARED SPECTROSCOPY 
 
Figure 12: FT-IR  Spectra  of Amlodipine Besylate 
No. Peak Intensity 
Corr. 
Intensity Base (H) Base (L) Area Corr. Area 
1 615.29 49.807 8.675 650.01 578.64 18.18 1.56 
2 754.17 52.441 5.04 777.31 740.67 9.306 0.594 
3 1095.57 36.867 6.635 1111 1066.64 16.678 1.139 
4 1205.51 30.914 15.075 1247.94 1147.65 41.19 7.372 
5 1498.69 32.808 6.312 1535.34 1469.76 29.02 2.341 
6 1618.28 31.129 5.02 1635.64 1571.99 28.06 1.17 
7 1676.14 29.653 4.095 1685.79 1658.78 13.429 0.822 
8 3415.93 13.913 1.841 3437.15 3188.33 179.432 -2.763 
Table 11:FT-IR  Spectra  of Amlodipine Besylate 
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Figure 13: FTIR spectra of Amlodipine Besylate + Ethyl cellulose + Poly Vinyl 
Pyrolidone 
No. Peak Intensity 
Corr. 
Intensity 
Base (H) Base (L) Area 
Corr.  
Area 
1 615.29 46.512 3.043 636.51 596 12.967 0.616 
2 752.24 47.88 1.616 779.24 736.81 13.146 0.311 
3 1099.43 32.778 2.289 1111 1068.56 19.389 0.602 
4 1205.51 31.664 7.657 1246.02 1147.65 44.445 4.361 
5 1300.02 35.456 2.875 1338.6 1280.73 24.723 0.844 
6 1487.12 33.802 0.362 1490.97 1475.54 7.182 0.033 
7 1670.35 30.177 0.191 1672.28 1666.5 3.004 0.01 
8 2926.01 22.425 1.583 2958.8 2517.1 243.977 -5.386 
9 3456.44 16.647 1.005 3618.46 3427.51 140.243 4.197 
 
Table 12: FTIR spectra of Amlodipine Besylate + Ethyl cellulose + Poly Vinyl 
Pyrolidone 
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Figure 14: FTIR spectra of Amlodipine Besylate + Ethyl Cellulose 
No. Peak Intensity 
Corr. 
Intensity 
Base (H) Base (L) Area 
Corr.   
Area 
1 397.34 48.057 0.744 416.62 393.48 7.145 0.081 
2 615.29 39.898 8.315 651.94 580.57 24.645 2.039 
3 752.24 43.86 4.45 775.38 738.74 12.174 0.803 
4 1095.57 27.968 6.113 1111 1068.56 20.875 1.562 
5 1203.58 22.785 15.46 1246.02 1147.65 51.235 10.055 
6 1301.95 31.41 6.961 1348.24 1284.59 28.073 1.934 
7 1496.76 26.873 7.014 1543.05 1473.62 34.985 3.081 
8 1676.14 24.329 3.182 1689.64 1654.92 20.171 0.897 
9 2926.01 19.428 1.579 2964.59 2519.03 270.63 -5.352 
10 3417.86 9.512 1.118 3439.08 3182.55 220.227 -4.597 
 
Table 13: FTIR spectra of Amlodipine Besylate + Ethyl Cellulose 
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Figure 15: FTIR spectra of Amlodipine Besylate + Ethyl Cellulose + Hydroxy 
Propyl Methyl Cellulose 
No. Peak Intensity 
Corr. 
Intensity 
Base (H) Base (L) Area Corr. Area 
1 615.29 17.06 5.855 644.22 597.93 31.877 2.348 
2 754.17 20.158 4.243 779.24 742.59 23.247 1.259 
3 1095.57 7.015 3.623 1111 1068.56 43.41 2.807 
4 1205.51 5.409 10.048 1247.94 1147.65 101.441 19.019 
5 1301.95 10.771 5.701 1350.17 1284.59 54.706 3.87 
6 1494.83 8.556 6.234 1544.98 1458.18 79.125 7.542 
7 1674.21 7.374 2.626 1687.71 1656.85 32.706 1.93 
8 3450.65 1.992 3.491 3678.25 3184.48 741.806 113.644 
 
Table14: FTIR spectra of Amlodipine Besylate + Ethyl Cellulose + Hydroxy Propyl 
Methyl Cellulose 
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Figure 16: FTIR spectra of Amlodipine Besylate + Hydroxy Propyl Methyl Cellulose 
No. Peak Intensity 
Corr. 
Intensity 
Base (H) Base (L) Area 
Corr.  
Area 
1 615.29 65.013 3.109 655.8 597.93 9.904 0.406 
2 1205.51 49.579 7.788 1246.02 1141.86 28.032 2.979 
3 1629.85 31.602 1.061 1633.71 1573.91 24.882 0.198 
4 1743.65 39.413 4.064 1770.65 1720.5 18.99 0.871 
5 2926.01 17.12 2.79 2980.02 2870.08 79.614 2.552 
6 3448.72 3.934 11.371 3695.61 3008.95 717.478 168.541 
 
Table 15: FTIR spectra of Amlodipine Besylate + Hydroxy Propyl Methyl Cellulose 
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Figure 17: FTIR spectra of Ethyl Cellulose 
 
No. Peak Intensity 
Corr. 
Intensity 
Base (H) Base (L) Area Corr. Area 
1 615.29 19.88 3.06 690.52 536.21 103.3 4.62 
2 1620.21 11.49 0.92 1627.92 1570.06 50.54 0.18 
3 3415.93 2.88 0.54 3435.22 3016.67 517.08 -25.39 
 
Table 16: FTIR spectra of Ethyl Cellulose 
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Figure 18: FTIR spectra of Poly Vinyl Pyrrolidone 
 
No. Peak Intensity 
Corr.  
Intensity 
Base (H) Base (L) Area 
Corr.  
Area 
1 619.15 20.77 1.81 661.58 534.28 83.81 2.16 
2 1618.28 14.21 1.35 1629.85 1571.99 46.35 0.59 
3 3415.93 6.89 1.01 3439.08 3265.49 183.58 1.01 
 
Table 17: FTIR spectra of Poly Vinyl Pyrrolidone 
 
 
  
 
  
 Observation Data 
 
 
 
 
 
77 
 
Cherraan’s College of Pharmacy, CBE 
 
STANDARD CALIBRATION CURVE OF AMLODIPINE BESILATE IN PHOSPHATE 
BUFFER pH 7.4 
 
Table 18: Standard graph of Amlodipine Besylate 
S.No Concentration µg/ml Absorbance 
1 0 0 
2 5 0.071 
3 10 0.143 
4 15 0.221 
5 20 0.274 
6 25 0.351 
7 30 0.423 
 
 
Figure 19:Standard graph of Amlodipine Besylate  
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Table 19:  Percentage Yield of Amlodipine Besylate Microparticles 
S.NO FORMULATION CODE PERCENTAGE YIELD 
(%) 
1 F1 45 
2 F2 95 
3 F3 53 
4 F4 65 
5 F5 70 
6 F6 75 
7 F7 78 
8 F8 82 
9 F9 96 
     (±S.D.and no. of determinations = 3 )        
               
Figure 20 :  Percentage yield of Amlodipine Besylate Microparticles 
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Table 20: Micromeritic Properties of Amlodipine Besylate Microparticles 
S.NO 
FORM. 
CODE 
ANGLE 
OF 
REPOSE 
BULK 
DENSITY 
TAPPED 
DENSITY 
CARR’S 
INDEX 
HAUSNER’S 
RATIO 
1 F1 20.42±0.20 0.78±0.64 0.84±0.73 10.1±0.84 1.05±0.54 
2 F2 26.82±0.80 0.51±0.042 0.49±0.012 9.52±0.026 1.078±0.32 
3 F3 20.66±0.36 0.79±0.62 0.83±0.72 7.73±0.29 1.14±0.011 
4 F4 19.66±0.20 0.62±0.30 0.68±0.36 10.1±0.84 1.17±0.046 
5 F5 19.11±0.20 0.73±0.46 0.67±0.32 10.05±0.54 1.16±0.032 
6 F6 28.40±0.21 0.625±0.068 0.724±0.058 12.67±0.049 1.10±0.013 
7 F7 32.00±0.63 0.641±0.52 0.769±0.074 16.65±0.064 1.15±0.018 
8 F8 25.60±0.05 0.54±0.32 0.56±0.012 10.13±0.41 1.12±0.015 
9 F9 24.92±0.32 0.49±0.013 0.55±0.014 9.12±0.012 1.122±0.032 
(±S.D.and no. of determinations = 3 ) 
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Table 21: Particle Size of Amlodipine Besylate Microparticles 
S.NO FORMULATION CODE PARTICLE SIZE µm 
1 F1 185 
2 F2 195 
3 F3 253 
4 F4 281 
5 F5 321 
6 F6 354 
7 F7 343 
8 F8 389 
9 F9 482 
(±S.D.and no. of determinations = 3 ) 
 
            
 
Figure 21: Particle Size of Amlodipine Besylate Microparticles 
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Table 22: Swelling Index(%) of Amlodipine Besylate Microparticles 
S.No Formulation code Swelling index (%) 
1 F1 190 
2 F2 195 
3 F3 189 
4 F4 175 
5 F5 165 
6 F6 182 
7 F7 185 
8 F8 186 
9 F9 196 
              
 
                 Figure 22: Swelling Index(%) of Amlodipine Besylate Microparticles 
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Table 23: Percentage Drug Loading of Amlodipine Besylate Microparticles 
S. NO FORMULATION CODE DRUG LOADING (%) 
1. F1 80 
2. F2 95 
3. F3 75 
4. F4 89 
5. F5 90 
6. F6 85 
7. F7 85 
8. F8 90 
9. F9 96 
 (±S.D.and no. of determinations = 3 ) 
             
Figure 23: Percentage Drug Loading or Amlodipine Besylate 
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Table 24: Entrapment Efficiency of Amlodipine  Besylate Microparticles 
S.NO FORMULATION CODE 
ENTRAPMENT 
EFFICIENCY (%) 
1 F1 25 
2 F2 95 
3 F3 30 
4 F4 44 
5 F5 53 
6 F6 58 
7 F7 65 
8 F8 80 
9 F9 96 
          
 
 
 
Figure 24: Entrapment Efficiency of Amlodipine  Besylate Microparticles 
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Table 25: In-Vitro Buoyancy (%) Studies 
S.No Formulation code Buoyancy (%) 
1 F1 87.5 
2 F2 96.0 
3 F3 88.5 
4 F4 83.5 
5 F5 88.5 
6 F6 88.2 
7 F7 89.2 
8 F8 91.21 
9 F9 97.00 
 
 
                   
Figure 25: In-Vitro Buoyancy (%) Studies 
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TABLE 26: In-Vitro Dissolution Profile of Amlodipine Besylate Microsphere Mean 
Cumulative Percentage Drug Release (%) 
S.No 
Time 
(hrs) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 1 14.84 11.92 14.01 10.18 10.91 11.65 10.11 10.25 11.82 
2 2 19.20 29.82 20.02 25.14 27.20 20.05 30.11 28.52 30.12 
3 3 24.26 42.01 23.01 38.26 43.05 30.01 42.45 39.42 43.15 
4 4 28.96 59.02 26.05 42.01 55.06 40.05 55.42 40.14 57.89 
5 5 32.27 68.01 31.08 45.01 65.01 52.06 60.14 52.15 69.12 
6 6 38.97 79.03 35.04 58.03 74.06 68.17 85.12 61.27 78.95 
7 7 42.01 87.05 42.05 60.02 85.23 70.18 87.15 75.38 89.01 
8 8 42.05 95.03 42.06 60.05 87.41 72.19 87.26 79.16 96.89 
(±S.D.and no. of determinations = 3 ) 
        
         
Figure 26 :In-vitro Dissolution Profile of Amlodipine Besylate Microparticle mean 
Cumulative Percentage Drug Release (%) 
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RESULT AND DISCUSSION 
 The principle objective of this research study was to formulate and evaluate 
sustained release microparticles of amlodipine besylate using  ethylcellulose, HPMC, 
Eudragit RS 100 and PVP polymer by solvent evaporation technique method. Various 
batches were made form batch (F1 to F9). 
 To achieve the above objective, ethylcellulose and Poly vinyl pyrrolidine was 
found to be suitable polymer due to its biocompatibility, good stability, and ease of 
fabrication. 
 Solvent evaporation method was employed to formulate microsphere due to its 
ease of fabrication without compromising the activity of the drug. Sustained release 
microspheres obtained by this method were found to be spherical, discrete and free 
flowing in nature. 
 The prepared Microspheres were evaluated for percentage yield, Micromeritic 
properties such as Angle of repose, Bulk density, Tapped density, compressibility index, 
Hausner’s ratio, particle size, Morphology analysis (SEM), swelling index (%), Drug 
content (%), Drug Entrapment efficiency(%), Buoyancy studies, in-vitro drug release and 
finally stability studies. 
FOURIER TRANSFORM-INFRARED SPECTROSCOPY 
 FT-IR study was carried out to see whether there is any incompatibility between 
drug and polymer and also to know whether there is complete physical adsorption of drug 
on to the polymer matrix without any mutual interaction. 
 The results obtained from the IR studies are shown in Fig No.12 Amlodipine 
showed prominent peaks. The same peaks were also observed in the physical mixture of 
drug & polymer and drug loaded Microspheres. 
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 After interpretation through the above spectra it was confirmed that there was no 
major shifting of functional peaks between the spectra of drug, polymer, physical mixture 
of drug and polymer and drug loaded microspheres. 
Drug excipients interaction study 
  Drug excipients interaction was studied using (FT-IR) fourier transformed 
infrared spectroscopy.  The characteristic peaks of the drug (fig 12 ) were observed at 
wave numbers   615.29cm
-1
, 754.17 cm
-1
, 1095.57 cm
-1
, 1205.01cm
-1
,1498.69 cm
-1 
,1618.28 cm
-1
, 1676.14 cm
-1
,3415.93 cm
-1
, in the functional group region of the pure drug 
spectrum. These characteristic peaks in the spectrum correspond to 615.29 cm
-1
 for   
stretching vibration of functional groups (OH, CH, CH3, CH2OH). These characteristic  
peaks also appear in the spectrum of amlodipine microparticles formulation at the same 
wave numbers indicating that there was no interaction between the drug and formulation 
excipients. 
PERCENTAGE YIELD 
  The low percentage yield in some formulation may be due to microspheres lost 
during the washing process.  Percentage yield of all formulations varies from F1 to F9  
which are shown in Table No.19 and indicates that F9 shows highest percentage yield of  
96% 
MICROMERITIC PROPERTIES 
Angle of repose   
Angle of repose value of all the formulations were in the range of 20.42±0.20 to 
25.60±0.05, which shows free flow nature of the prepared microsphere, the results were 
shown in table no.20. 
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 Bulk density and Tapped density 
It has been stated that, bulk density values less than 1.2 gm/cm
3
 indicate good 
glow and values greater than 1.5 gm/cm3 indicate poor flow characteristic.  It is seen 
from table No. 21 that the bulk density values are less than 1.2 gm/cm3 indicating good 
flow characteristics of the microspheres. 
Compressibility index 
The Carr’s index of all the formulations was less than 20, i.e from 10.1±0.84 to 
10.13±0.41, which inidicates good flow properties and compressibility 
Hausner’s ratio 
Hausner’s ratio was ranging from 1.05±0.54 to 1.12±0.015 i.e., all the preparation 
showed that they had good flow properties. The improvement in flow properties suggests 
that the microspheres can be easily handled during processing. The results were shown in 
table no.20 
PARTICLE SIZE AND MORPHOLOGY ANALYSIS (SEM) 
Here, keeping drug ratio constant and varied polymer ratio as the polymer 
concentration increases, viscosity increases, which influences the interaction between 
disperse phase and dispersion medium and affects the size concentration, there was 
increase in relative viscosity so as resulted in an increase in mean particle size. The 
particle size of drug loaded batches, ranges from  185 to 489µm.  The mean particle size 
of all the formulations was shown in table No: 21 
SURFACE MORPHOLOGY 
 SEM was performed on the prepared Amlodipine besylate microspheres to access 
their surface and morphological characteristics as shown in fig: 27 Scanning Electron 
Microphotographs indicate that microsphere were spherical and discrete. 
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Figure: 27 SEM analysis for formulation F9 
SWELLING INDEX (%) 
 The swelling index for all F1 to F9 formulations are ranges from 190 to 186% 
 DRUG CONTENT (%) 
Loading efficiency of drug loaded batches was found to be 80% to 96 %.  The 
drug loading efficiency of all formulations were shown in table No.23  which indicates 
that the highest drug loading was found to be F9 as 96%  
DRUG ENTRAPMENT:  
The microspheres exhibited an increase in drug entrapment with an increase in the 
proper ratio up to a particular concentration. A decrease in drug entrapment was observed 
after that point due to saturation  capacity of the polymer.  The entrapment efficiency of 
drug loaded batches, ranges from 25 to 95. The results were shown in table No.24 
The maximum drug entrapped in the F9 formulation, 96% .  The results are shown in 
table no.24 
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BUOYANCY STUDIES:  
 In this study the values ranges from 87.5 to 97.00 
IN-VITRO DISSOLUTION STUDY 
 Cumulative percentage release of amlodipine besylate loaded microsphere carried 
out in 1.2 pH HCl buffer for two hours and then 7.4 pH phosphate buffer upto 8, hours.   
 The release rate was decreased by increasing the polymer concentration and 
particle size. 
The rapid release was obtained in formulation F9 due to low concentration of 
polymer and size of the particle results in higher contact of dissolution medium due to 
increased surface area. 
 Drug release from all the formulations was slow and sustained over 8  hours. By 
the end of 8 hours, F1, F2, F3, F4, F5, F6,F7, F8,F9  released 96.89 of loaded drug 
respectively.  The polymer/drug F9 showed better sustained release pattern and drug 
entrapment and found to be most suitable among all the other formulations. In-vitro 
profiles of all the formulations have been shown in fig no.26 
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STABILITY STUDIES 
The stability studies indicates the significant difference between the release 
patterns of microsphere at 40°C and RH and at room temperature for one month. 
The stability studies were carried out at and optimized formulation, i.e, from F9 
forumulation. The formulation was store at (40°C±2°C at 75% RH ± 5 %) for 1 months.   
Sample were withdrawn and retested for drug release and was compare with the 
formulation diffusion profile. 
Table 27. Stability studies for formulated floating microparticles of Amlodipine 
Besylate 
Characters Initial month After 1 month 
Appearance Spherical Spherical 
Solubility Soluble in phosphate buffer Solubile in phosphate buffer 
Colour Half white Half white 
Particle size 482 489 
Swelling index 196 196 
In-vitro drug release in 
hours 
Mean cumulative release in percentage (%) 
1 11.82 11.93 
2 30.12 30.45 
3 43.15 43.95 
4 57.89 58.12 
5 69.12 68.95 
6 78.95 79.01 
7 89.01 89.25 
8 96.89 96.45 
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SUMMARY AND CONCLUSION 
 Floating  amlodipine besylate microparticles using polymer ethylcellulose, 
HPMC, Poly vinyl pyrrolidine and Eudragit RS 100 was developed by solvent 
evaporation method and it was found to be a suitable floating oral drug delivery system in 
terms of particle size distribution, drug loading capacity and Sustained release amlodipine 
besylate microparticles obtained was spherical in shape, discrete and free flow in nature. 
It can be concluded that,  
 Polymer-drug ratio influence the particle size as well as drug release 
pattern of microsphere.  
 Entrapment efficiency of drug loaded batches F1 to F9 were determined 
and it was found that  F2 and F9 had a better drug entrapment efficiency 
of  95% and 96% 
 Drug loading efficiency was better with F9 showed 96% 
 Percentage yield from all the formulation were high and F9 showed good 
percentage yield of 96% 
 Flow properties were determined for all the formulations F1 to F9. The 
result of Carr’s index and angle of repose values indicated that all the 
formulations showed good flow properties. 
 In-vitro drug release from all the formulations was found to be slow and 
sustained over the period of 8 hours was found to be 96.89%  
 Stability studies of formulated Amlodipine microparticles was done at 40° 
C± 2°C and 75%±5 RH. Evaluating initial month and after one month 
founded that there is no significant changes in appearance, solubility, 
colour, particle size, swelling index, in-vitro drug release 
 Decided  to do in-vivo studies in future. 
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